Sustained release dosage forms for jak1 inhibitor

JP2024166266AInactive Publication Date: 2024-11-28INCYTE HOLDINGS CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024153579
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2013-12-06
Filing Date
2024-09-06
Publication Date
2024-11-28
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Benefits of technology

【0218】 この効果/副作用プロファイルは、JAK2シグナル伝達が造血に結びつくために、1日1回用量がトラフで低いJAK2阻害を伴い最大のJAK1シグナル伝達(効果に結びつく)を達成することに起因し得ると考えられる。この仮説は、様々な用量での式の化合物についてのPK由来JAK1(IL-6)及びJAK2(TPO)阻害データにより支持される(表7)。具体的には、600mg 1日1回用量は、200mg 1日2回及び400mg 1日2回用量に対して同様の平均IL-6阻害を示した(61%対64%及び69%)が、200mg 1日2回及び400mg 1日2回用量と比較してトラフTPO阻害は低かった(4%対13%及び16%)。600mg 1日1回用量のトラフIL-6阻害も、200mg 1日2回及び400mg 1日2回用量のトラフIL-6阻害より低く、これは1日1回用量からの感染の低下があり得ることを示唆する。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024166266000022
    Figure 2024166266000022
  • Figure 2024166266000023
    Figure 2024166266000023
  • Figure 2024166266000024
    Figure 2024166266000024
Patent Text Reader

Abstract

To provide sustained release dosage forms comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof, and doses and methods related thereto.SOLUTION: This invention relates to sustained release dosage forms comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] This application claims the benefit of priority to U.S. Provisional Patent Application No. 61 / 863,325, filed August 7, 2013, and U.S. Provisional Patent Application No. 61 / 913,066, filed December 6, 2013, each of which is incorporated by reference in its entirety herein.

[0002] The present application relates to sustained release dosage forms comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof, and dosages and methods related thereto. [Background technology]

[0003] Protein kinases (PKs) regulate diverse biological processes including cell proliferation, survival, differentiation, organogenesis, morphogenesis, angiogenesis, tissue repair, and regeneration, among others. Protein kinases also play specialized roles in a host of human diseases, including cancer. Cytokines, small polypeptides or glycoproteins, regulate many pathways involved in the host inflammatory response to sepsis. Cytokines affect cell differentiation, proliferation, and activation, orchestrating both pro- and anti-inflammatory responses, allowing the host to respond appropriately to pathogens. Signal transduction of a wide range of cytokines involves the Janus kinase family of protein tyrosine kinases (JAK) and signal transducers and activators of transcription (STAT). Four mammalian JAKs are known: JAK1 (Janus kinase-1), JAK2, JAK3 (also known as Janus kinase, leukocyte; JAKL; and L-JAK), and TYK2 (protein tyrosine kinase 2).

[0004] Cytokine-stimulated immune and inflammatory responses contribute to disease pathogenesis: conditions such as severe combined immunodeficiency (SCID) result from suppression of the immune system, while hyperactive or inappropriate immune / inflammatory responses contribute to the pathology of autoimmune diseases (e.g., asthma, systemic lupus erythematosus, thyroiditis, myocarditis) and diseases such as scleroderma and osteoarthritis (Non-Patent Document 1).

[0005] Loss of JAK expression is associated with many disease states. For example, Jak1- / - mice are growth retarded from birth and are unable to lactate, resulting in perinatal death (Non-Patent Document 2). Jak2- / - mouse fetuses are anemic and die approximately 12.5 days after mating due to a critical lack of erythropoiesis.

[0006] The JAK / STAT pathway, particularly all four JAKs, are believed to play a role in the pathogenesis of asthmatic responses, chronic obstructive pulmonary disease, bronchitis, and other related lower airway inflammatory diseases. Several cytokines that signal through JAKs have been linked to upper airway inflammatory diseases / conditions, such as diseases / conditions affecting the nose and paranasal sinuses (e.g., rhinitis and sinusitis), whether or not they are classical allergic responses. The JAK / STAT pathway has also been implicated in ocular inflammatory diseases / conditions and chronic allergic responses. Activation of JAK / STAT in cancer can occur by stimulation with cytokines (e.g., IL-6 or GM-CSF) or by a decrease in endogenous inhibitors of JAK signaling, such as SOCS (suppressor or cytokine signaling) or PIAS (protein inhibitor of activated STAT) (Non-Patent Document 3). Activation of STAT signaling, as well as other downstream pathways of JAK (e.g., Akt), has been correlated with poor prognosis in many cancer types (Non-Patent Document 4). Elevated levels of circulating cytokines that signal through JAK / STAT play a causal role in cachexia and / or chronic fatigue. Thus, JAK inhibition may be beneficial for cancer patients, extending beyond potential antitumor activity.

[0007] JAK2 tyrosine kinase may be beneficial for patients with myeloproliferative disorders such as polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis with myeloid metaplasia (MMM) (Non-Patent Document 5). Inhibition of JAK2V617F kinase reduces hematopoietic cell proliferation, indicating that JAK2 is a potential target for pharmacological inhibition in patients with PV, ET, and MMM.

[0008] Inhibition of JAKs may be beneficial for patients with skin immune disorders such as psoriasis, and skin sensitization. The persistence of psoriasis is thought to depend on a number of inflammatory cytokines, in addition to various chemokines and growth factors (Non-Patent Document 6), many of which signal through JAKs (Non-Patent Document 7). [Prior art documents] [Non-patent literature]

[0009] [Non-Patent Document 1] Ortmann, RA, T. Cheng et al. (2000) Arthritis Res 2(1):16-32 [Non-Patent Document 2] Rodig, SJ, MAMeraz et al. (1998) Cell 93(3):373-83 [Non-Patent Document 3] Boudny, V., and Kovarik, J., Neoplasm.49:349-355, 2002 [Non-Patent Document 4] Bowman, T et al. Oncogene 19:2474-2488, 2000 [Non-Patent Document 5] Levin et al., CancerCell, vol. 7, 2005: 387-397 [Non-Patent Document 6] JCI,113:1664-1675 [Non-Patent Document 7] Adv Pharmacol.2000;47:113-74 Summary of the Invention [Problem to be solved by the invention]

[0010] Improved formulations for administering JAK kinases are needed to enhance or suppress immune and inflammatory pathways, and because of the utility of compounds that inhibit JAK (e.g., immunosuppressants for organ transplants) in treating autoimmune diseases, diseases with hyperactive inflammatory responses (e.g., eczema), allergies, cancers (e.g., prostate, leukemia, multiple myeloma), and some immune responses caused by other therapeutic agents (e.g., skin rashes or contact dermatitis or diarrhea). The dosage forms and doses and methods described herein address this need and other objectives. [Means for solving the problem]

[0011] JAK inhibitors are described in U.S. Patent Application Serial No. 13 / 043,986, filed March 9, 2011 (US2011 / 0224190), which is incorporated by reference in its entirety, and include {{1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, as shown in Formula I below. [ka] I

[0012] The present application specifically provides sustained release dosage forms comprising about 25 mg to about 600 mg (e.g., 25 mg, 100 mg, 200 mg, 300 mg, or 600 mg) of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof, on a free base basis.

[0013] The present invention further provides one or more sustained release dosage forms each comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof, wherein the one or more sustained release dosage forms together provide a patient with a once-daily oral dosage of about 400 mg to about 600 mg, on a free base basis, of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof.

[0014] The present invention also provides a dosage comprising one or more sustained release dosage forms each comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof, wherein the dosage provides a patient with a once-daily oral dosage of about 400 mg to about 600 mg, on a free base basis, of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof.

[0015] The application further provides one or more sustained release dosage forms as described herein, which together provide a patient with a once-daily oral dosage of about 600 mg, on a free base basis, of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof.

[0016] The application also provides dosages comprising one or more sustained release dosage forms as described herein, which together provide a patient with a once daily oral dosage of about 600 mg, based on the free base, of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutical acceptable salt thereof.

[0017] The application further provides a method of treating an autoimmune disease, cancer, a myeloproliferative disease, an inflammatory disease, a bone resorption disease, or organ transplant rejection in a patient in need thereof, comprising orally administering to the patient one or more sustained release dosage forms described herein.

[0018] The present application relates to a method of treating an autoimmune disease, cancer, a myeloproliferative disease, an inflammatory disease, a bone resorption disease, or organ transplant rejection in a patient in need thereof, comprising administering to the patient a compound comprising the free base group of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutical acceptable salt thereof. orally administering to the patient a once daily dose of about 400 mg to about 600 mg, wherein the dose comprises one or more sustained release dosage forms each comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof.

[0019] The application further provides a method of treating an autoimmune disease, cancer, a myeloproliferative disease, an inflammatory disease, a bone resorption disease, or organ transplant rejection in a patient in need thereof, comprising orally administering to the patient one or more sustained release doses described herein.

[0020] The application also provides a method of treating an autoimmune disease, cancer, a myeloproliferative disease, an inflammatory disease, a bone resorption disease, or organ transplant rejection in a patient in need thereof, the method comprising orally administering to the patient one or more sustained release dosage forms of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof, as a once-daily dosage of about 600 mg, on a free base basis. [Brief description of the drawings]

[0021] [Figure 1] 1A-C show plasma concentrations (mean ± SE) for the compound of formula I in healthy subjects receiving a single dose of 300 mg IR capsule (1A: Cohorts 1-4, fasted), SR1, SR2, SR3, and SR4 tablets (2B: Cohorts 1-4, fasted; and 2C: Cohorts 1-4, high-fat meal fed). [Diagram 2] Figures 2A-B show the PK profiles (mean ± SE) of a single 300 mg dose of SR3 (2A: Cohort 3, SR3, fasted vs. high-fat meal; and 2B: Cohort 5, SR3, fasted vs. medium-fat meal). [Diagram 3] FIG. 3 shows a comparison of the PK profiles (mean±SE) between 25 mg and 100 mg SR3 tablets (treatment A vs. C) and the effect of a high fat meal on the 25 mg SR3 tablets (treatment B vs. A). [Figure 4] FIG. 4 shows the percent change from baseline in hemoglobin for several dosing regimens of extended release tablets versus placebo. [Diagram 5]Figure 5(a) shows the percentage of patients by dose cohort (100 mg bid, 200 mg bid, and 600 mg qd) who achieved a 50% or greater reduction in Total Symptom Score (TSS) at week 12. Figure 5(b) shows the percentage change in Total Symptom Score (TSS) from baseline at week 12 by dose cohort (100 mg bid, 200 mg bid, and 600 mg qd). [Figure 6] Figure 6(a) shows the mean hemoglobin levels over time by dose cohort (100 mg bid, 200 mg bid, and 600 mg qd). Figure 6(b) shows the mean hemoglobin levels (g / dL) over time at 48 weeks by dose cohort (100 mg bid, 200 mg bid, and 600 mg qd). Figure 6(c) shows the mean hemoglobin levels (g / dL) over time at 48 weeks by dose cohort, averaged across the three dose cohorts, compared to individuals receiving placebo or ruxolitinib. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0022] The present application provides a sustained release dosage form comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof. In some embodiments, the present application provides a sustained release dosage form comprising about 25 mg to about 600 mg of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof, on a free base basis.

[0023] In some embodiments, the sustained release dosage form comprises about 300 mg of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof, on a free base basis.

[0024] In some embodiments, the sustained release dosage form comprises about 200 mg of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof, on a free base basis.

[0025] In some embodiments, the sustained release dosage form comprises about 100 mg of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof, on a free base basis.

[0026] In some embodiments, the sustained release dosage form comprises about 300 mg of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile adipate salt on a free base basis.

[0027] In some embodiments, the sustained release dosage form comprises about 200 mg of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile adipate on a free base basis.

[0028] In some embodiments, the sustained release dosage form comprises about 100 mg of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile adipate salt on a free base basis.

[0029] In some embodiments of a sustained release dosage form containing about 100 mg, oral administration of three of said dosage forms to a fasted individual provides a mean peak plasma concentration (C max ) is about 100 nM to about 1000 nM. As used in this context, oral administration means that a single dose is administered to an individual (in this case 3×100 mg) and the PK parameters are calculated from measurements of plasma concentrations over time. In this context, the PK parameters (in this case C max ) is used to characterize a single sustained release dosage form (i.e., a single dosage form is claimed, not three dosage forms).

[0030] In some embodiments of a sustained release dosage form containing about 100 mg, oral administration of three of said dosage forms to a fasted individual provides a mean peak plasma concentration (C max ) is about 400 nM to about 700 nM.

[0031] In some embodiments of a sustained release dosage form containing about 100 mg, oral administration of three of said dosage forms to a fasted individual provides the mean time to peak plasma concentration (T max ) is from about 0.5 hours to about 3 hours.

[0032] In some embodiments of a sustained release dosage form containing about 100 mg, oral administration of three of said dosage forms to a fasted individual provides the mean time to peak plasma concentration (T max ) is at least 0.5 hours.

[0033] In some embodiments of a sustained release dosage form containing about 100 mg, oral administration of three of said dosage forms to a fasted individual provides a mean peak plasma concentration (C max ) mean 12-hour plasma concentration (C 12h ) is from about 5 to about 50.

[0034] In some embodiments of a sustained release dosage form containing about 100 mg, oral administration of three of said dosage forms to a fasted individual provides a mean peak plasma concentration (C max ) mean 12-hour plasma concentration (C 12h) is from about 9 to about 40.

[0035] In some embodiments of a sustained release dosage form containing about 100 mg, oral administration of three of said dosage forms to a fasted individual provides a mean peak plasma concentration (C max ) mean 12-hour plasma concentration (C 12h ) is from about 15 to about 30.

[0036] In some embodiments of a sustained release dosage form containing about 100 mg, oral administration of three of said dosage forms to a fasted individual provides a mean half-life (t 1 / 2 ) is about 5 hours to about 15 hours.

[0037] In some embodiments of a sustained release dosage form containing about 100 mg, oral administration of three of said dosage forms to a fasted individual provides a mean half-life (t 1 / 2 ) is about 7 hours to about 12 hours.

[0038] In some embodiments of a sustained release dosage form containing about 100 mg, oral administration of three of said dosage forms to a fasted individual provides a mean half-life (t 1 / 2) is from about 1 hour to about 20 hours.

[0039] In some embodiments of a sustained release dosage form containing about 100 mg, oral administration of three of said dosage forms to a fasted individual provides an average bioavailability (AUC 0-∞ ) is from about 1000 nM x hr to about 4000 nM x hr.

[0040] In some embodiments of a sustained release dosage form containing about 100 mg, oral administration of three of said dosage forms to a fasted individual provides an average bioavailability (AUC 0-∞ ) is about 1500 nM x hr to about 3100 nM x hr.

[0041] In some embodiments of a sustained release dosage form containing about 100 mg, oral administration of three of said dosage forms to an individual after a high fat meal provides a mean peak plasma concentration (C max ) is from about 200 nM to about 2000 nM.

[0042] In some embodiments of a sustained release dosage form containing about 100 mg, oral administration of three of said dosage forms to an individual after a high fat meal provides a mean peak plasma concentration (C max ) is from about 500 nM to about 1500 nM.

[0043] In some embodiments of a sustained release dosage form containing about 100 mg, oral administration of three of said dosage forms to an individual after a high fat meal provides the mean time to peak plasma concentration (T max ) is from about 1 hour to about 9 hours.

[0044] In some embodiments of a sustained release dosage form containing about 100 mg, oral administration of three of said dosage forms to an individual after a high fat meal provides the mean time to peak plasma concentration (T max ) is at least 1.5 hours.

[0045] In some embodiments of a sustained release dosage form containing about 100 mg, oral administration of three of said dosage forms to an individual after a high fat meal provides a mean peak plasma concentration (C max ) mean 12-hour plasma concentration (C 12h ) is from about 10 to about 70.

[0046] In some embodiments of a sustained release dosage form containing about 100 mg, oral administration of three of said dosage forms to an individual after a high fat meal provides a mean peak plasma concentration (C max ) mean 12-hour plasma concentration (C 12h ) is from about 15 to about 50.

[0047] In some embodiments of a sustained release dosage form containing about 100 mg, oral administration of three of said dosage forms to an individual after a high fat meal provides a mean peak plasma concentration (C max ) mean 12-hour plasma concentration (C 12h ) is from about 25 to about 45.

[0048] In some embodiments of a sustained release dosage form containing about 100 mg, oral administration of three of said dosage forms to an individual after a high fat meal provides a mean half-life (t 1 / 2 ) is about 1 hour to about 7 hours.

[0049] In some embodiments of a sustained release dosage form containing about 100 mg, oral administration of three of said dosage forms to an individual after a high fat meal provides a mean half-life (t1 / 2 ) is about 2 hours to about 5 hours.

[0050] In some embodiments of a sustained release dosage form containing about 100 mg, oral administration of three of said dosage forms to an individual after a high fat meal provides the mean bioavailability (AUC 0-∞ ) is from about 2000 nM x hr to about 5000 nM x hr.

[0051] In some embodiments of a sustained release dosage form containing about 100 mg, oral administration of three of said dosage forms to an individual after a high fat meal provides the mean bioavailability (AUC 0-∞ ) is about 3000 nM x hr to about 4000 nM x hr.

[0052] In some embodiments, C max is about 15% to about 30%, wherein the one or more immediate release dosage forms and the one or more sustained release dosage forms are administered orally independently as single doses to a fasted individual and the same dose of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt, is administered.

[0053] In some embodiments, C maxis about 15% to about 30%, wherein the one or more immediate release dosage forms and the one or more sustained release dosage forms are administered orally independently as single doses to a fasted individual and the same dose of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt, is administered.

[0054] In some embodiments, the AUC 0-∞ is from about 40% to about 55%, wherein the one or more immediate release dosage forms and the one or more sustained release dosage forms are orally administered separately as single doses to a fasted individual, wherein the same dose of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt, is administered.

[0055] In some embodiments, the C of a sustained release dosage form administered orally to an individual after a high fat meal versus a sustained release dosage form administered orally to a fasting individual. max The geometric mean percentage for is about 150% to about 250%.

[0056] In some embodiments, the AUC of a sustained release dosage form orally administered to an individual after a high fat meal versus a sustained release dosage form orally administered to a fasting individual. 0-∞ The geometric mean percentage for is about 125% to about 170%.

[0057] In some embodiments, the sustained release dosage form of the present invention may include a sustained release matrix former. Examples of sustained release matrix formers include cellulose ethers, such as hydroxypropyl methylcellulose (HPMC, hypromellose), which is a high viscosity polymer, and methylcellulose. Examples of hydroxypropyl methylcellulose include Methocel™ K15M, Methocel™ K4M, Methocel™ K100LV, Methocel™ E3, Methocel™ E5, Methocel™ E6, Methocel™ E15, Methocel™ E50, Methocel™ E10M, Methocel™ E4M, and Methocel™ E10M. In some embodiments, the sustained release dosage form includes one or more hypromelloses. In some embodiments, the sustained release dosage form comprises a first hypromellose characterized by having an apparent viscosity of about 80 cP to about 120 cP at a 2% concentration in water and a second hypromellose characterized by having an apparent viscosity of about 3000 cP to about 5600 cP at a 2% concentration in water. In some embodiments, the sustained release dosage form comprises about 8% to about 20% by weight of one or more hypromelloses. In some embodiments, the sustained release dosage form comprises about 10% to about 15% by weight of one or more hypromelloses.

[0058] In some embodiments, the sustained release dosage form of the present invention can further comprise one or more fillers, glidants, disintegrants, binders, or lubricants as inactive ingredients. In some embodiments, the filler comprises microcrystalline cellulose, lactose monohydrate, or both. In some embodiments, the sustained release dosage form comprises about 16% to about 22% by weight of microcrystalline cellulose. In some embodiments, the sustained release dosage form comprises about 45% to about 55% by weight of lactose monohydrate.

[0059] In some embodiments, the lubricant can be present in the dosage form of the present invention in an amount of 0 to about 5% by weight. Non-limiting examples of lubricants include magnesium stearate, stearic acid (stearin), hydrogenated oil, polyethylene glycol, sodium stearyl fumarate, and glyceryl behenate. In some embodiments, the formulation includes magnesium stearate, stearic acid, or both. In some embodiments, the sustained release dosage form includes about 0.3% to about 0.7% by weight of magnesium stearate.

[0060] In some embodiments, a glidant may be present in the dosage form. In some embodiments, the glidant may be present in the dosage form of the present invention in an amount of 0 to about 5% by weight. Non-limiting examples of glidants include talc, colloidal silicon dioxide, and cornstarch. In some embodiments, the glidant is colloidal silicon dioxide.

[0061] In some embodiments, the film coating agent may be present in an amount of 0 to about 5% by weight. Non-limiting illustrative examples of film coating agents include hypromellose or polyvinyl alcohol-based coatings, along with titanium dioxide, talc, and optionally colorants, in some commercially available complete coating systems.

[0062] In some embodiments, the sustained release dosage form comprises pregelatinized starch.

[0063] In some embodiments, the sustained release dosage form is a tablet.

[0064] In some embodiments, the sustained release dosage form is prepared by a process comprising wet granulation.

[0065] In some embodiments, the sustained release dosage form comprises one or more excipients independently selected from hypromellose and microcrystalline cellulose.

[0066] In some embodiments, the sustained release dosage form comprises one or more excipients independently selected from hypromellose, microcrystalline cellulose, magnesium stearate, lactose, and lactose monohydrate.

[0067] In some embodiments, the sustained release dosage form comprises one or more excipients independently selected from hypromellose, microcrystalline cellulose, magnesium stearate, lactose, lactose monohydrate, and pregelatinized starch.

[0068] The present invention further provides one or more sustained release dosage forms each comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof, wherein the one or more sustained release dosage forms together provide a patient with a once-daily oral dosage of about 400 mg to about 600 mg, on a free base basis, of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof.

[0069] The present invention further provides a dosage comprising one or more sustained release dosage forms each comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof, wherein said dosage provides a patient with a once-daily oral dosage of about 400 mg to about 600 mg, on a free basis, of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof.

[0070] The application further provides one or more sustained release dosage forms as described herein, which together provide a patient with a once-daily oral dosage of about 600 mg, on a free base basis, of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof.

[0071] The application further provides one or more sustained release dosage forms as described herein, together providing a patient with a once daily oral dosage of about 500 mg, on a free base basis, of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof.

[0072] The application further provides one or more sustained release dosage forms as described herein, which together provide a patient with a once-daily oral dosage of about 400 mg, on a free base basis, of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof.

[0073] In some embodiments, the one or more sustained release dosage forms are provided in six dosage forms of about 100 mg of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof, based on the free base. In some embodiments, the one or more sustained release dosage forms are provided in three dosage forms of about 200 mg of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma-ceutically acceptable salt thereof, based on the free base. In some embodiments, the one or more sustained release dosage forms are provided in two dosage forms of about 300 mg of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof, based on the free base. In some embodiments, the one or more sustained release dosage forms are provided in one dosage form of about 600 mg of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma-ceutically acceptable salt thereof, based on the free base.

[0074] The application also provides dosages comprising one or more sustained release dosage forms described herein that provide a patient with a once daily oral dosage of about 600 mg, on a free base basis, of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutical acceptable salt thereof.

[0075] The application also provides dosages comprising one or more sustained release dosage forms described herein that provide a patient with a once daily oral dosage of about 500 mg, on a free base basis, of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutical acceptable salt thereof.

[0076] The application also provides dosages comprising one or more sustained release dosage forms described herein that provide a patient with a once daily oral dosage of about 400 mg, on a free base basis, of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutical acceptable salt thereof.

[0077] In some embodiments, the dose comprises six dosage forms of about 100 mg of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof, on a free base basis. In some embodiments, the dose comprises three dosage forms of about 200 mg of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma-ceutically acceptable salt thereof, on a free base basis. In some embodiments, the dose comprises two dosage forms of about 300 mg on a free basis of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof. In some embodiments, the dose comprises one dosage form of about 600 mg on a free basis of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma-ceutically acceptable salt thereof.

[0078] The application further provides kits containing one or more sustained release dosage forms as described herein, which together provide a patient with a once-daily oral dosage of about 400 mg to about 600 mg, on a free base basis, of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutical acceptable salt thereof. In some embodiments, the kit further comprises instructions for administering the one or more sustained release dosage forms as a once-daily dose of about 400 mg to about 600 mg of the free base of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof.

[0079] The application further provides a kit comprising one or more sustained release dosage forms as described herein, which together provide a patient with a once-daily oral dosage of about 600 mg, on a free base basis, of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutical acceptable salt thereof. In some embodiments, the kit further comprises instructions for administering the one or more sustained release dosage forms as a once-daily dose of about 600 mg of the free base of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof.

[0080] The present application further provides a kit comprising one or more sustained release dosage forms as described herein, which together provide a patient with a once-daily oral dosage of about 500 mg, on a free base basis, of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof. In some embodiments, the kit further comprises instructions for administering the one or more sustained release dosage forms as a once-daily dose of about 600 mg of the free base of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof.

[0081] The application further provides a kit comprising one or more sustained release dosage forms as described herein, which together provide a patient with a once-daily oral dosage of about 400 mg, on a free base basis, of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof. In some embodiments, the kit further comprises instructions for administering the one or more sustained release dosage forms as a once-daily dose of about 600 mg of the free base of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof.

[0082] In some embodiments, the kit includes six dosage forms of about 100 mg of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof, based on the free base. In some embodiments, the kit includes three dosage forms of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof, based on the free base ... In some embodiments, the kit includes two dosage forms of about 300 mg of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof, based on the free base. In some embodiments, the kit includes one dosage form of about 600 mg of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof, based on the free base.

[0083] As used herein, "sustained release" is used as commonly understood in the art and refers to a formulation designed to slowly release active ingredients into the patient after oral administration.

[0084] As used herein, "dose" refers to the total amount of a compound of formula I that is orally administered to an individual or patient. A dose may be in a single dosage form, or in multiple dosage forms (e.g., a 600 mg dose may be one 600 mg dosage form, two 300 mg dosage forms, three 200 mg dosage forms, six 100 mg dosage forms, etc.). Thus, a dose may refer to multiple pills that are taken by a patient at about the same time.

[0085] As used herein, "fasted individual" means an individual who has fasted for at least 10 hours prior to administration of a dose.

[0086] As used herein, "average" when preceding a pharmacokinetic value (e.g., mean C max ), unless otherwise indicated, represent the arithmetic mean of pharmacokinetic values ​​taken from a population of patients.

[0087] As used herein, "C max " means maximum observed plasma concentration.

[0088] As used herein, "C 12h " refers to plasma concentration 12 hours after administration.

[0089] As used herein, "T max " refers to the time at which maximum plasma concentration was observed.

[0090] As used herein, "T 1 / 2 " refers to the time at which the plasma concentration is half of the maximum observed value.

[0091] As used herein, "AUC" refers to the area under the plasma concentration-time curve, which is a measure of total bioavailability.

[0092] As used herein, "AUC 0-∞ " refers to the area under the plasma concentration-time curve extrapolated to infinity.

[0093] As used herein, "AUC 0-t" refers to the area under the plasma concentration-time curve from time 0 to the last quantifiable time point of plasma concentration (usually about 12 to 36 hours).

[0094] As used herein, "AUC 0-τ " refers to the area under the plasma concentration-time curve from time 0 to the time of the next dose.

[0095] As used herein, "Cl / F" refers to oral clearance.

[0096] The present invention also includes pharma- ceutically acceptable salts of the compounds described herein. As used herein, "pharma- ceutically acceptable salts" refers to derivatives of the compounds of the present disclosure, in which the parent compound is modified by converting an existing acid or base moiety into its salt form. Examples of pharma- ceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharma- ceutically acceptable salts of the present invention include non-toxic salts of the parent compound, for example, formed from non-toxic inorganic or organic acids. The pharma- ceutically acceptable salts of the present invention can be synthesized from the parent compound containing a basic or acidic moiety by conventional chemical methods. Typically, such salts can be prepared by reacting the free acid or free base forms of these compounds with a stoichiometric amount of a suitable base or acid in water or an organic solvent, or in a mixture of the two; generally, non-aqueous media such as ether, ethyl acetate, alcohol (e.g., methanol, ethanol, isopropanol, or butanol) or acetonitrile (ACN) are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418, and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated by reference in its entirety. In some embodiments, the compounds described herein include N-oxide forms.

[0097] method The application further provides a method of treating an autoimmune disease, cancer, a myeloproliferative disease, an inflammatory disease, a bone resorption disease, or organ transplant rejection in a patient in need thereof, comprising orally administering to the patient one or more sustained release dosage forms described herein.

[0098] The present application relates to a method of treating an autoimmune disease, cancer, a myeloproliferative disease, an inflammatory disease, a bone resorption disease, or organ transplant rejection in a patient in need thereof, comprising administering to a patient a compound of formula (I) or (II) of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutical acceptable salt thereof, on a free base basis. orally administering to the patient a once daily dose of about 400 mg to about 600 mg at 25° C., wherein the dose comprises one or more sustained release dosage forms each comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof. The application further provides a method of treating an autoimmune disease, cancer, a myeloproliferative disease, an inflammatory disease, a bone resorption disease, or organ transplant rejection in a patient in need thereof, comprising orally administering to the patient one or more sustained release doses described herein.

[0099] The application also provides a method of treating an autoimmune disease, cancer, a myeloproliferative disease, an inflammatory disease, a bone resorption disease, or organ transplant rejection in a patient in need thereof, comprising orally administering to the patient one or more sustained release dosage forms of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutical acceptable salt thereof, as a once-daily dosage of about 600 mg, based on the free base.

[0100] The application also provides a method of treating an autoimmune disease, cancer, a myeloproliferative disease, an inflammatory disease, a bone resorption disease, or organ transplant rejection in a patient in need thereof, comprising orally administering to the patient one or more sustained release dosage forms of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutical acceptable salt thereof, as a once-daily dosage of about 500 mg, based on the free base.

[0101] The application also provides a method of treating an autoimmune disease, cancer, a myeloproliferative disease, an inflammatory disease, a bone resorption disease, or organ transplant rejection in a patient in need thereof, comprising orally administering to the patient one or more sustained release dosage forms of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutical acceptable salt thereof, as a once-daily dosage of about 400 mg, based on the free base.

[0102] In some embodiments of the method in the previous three paragraphs, the one or more sustained release dosage forms are provided in six dosage forms of about 100 mg on a free base basis of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutical acceptable salt thereof. In some embodiments of the method in the previous three paragraphs, one or more sustained release dosage forms are provided in three dosage forms of about 200 mg on a free base basis of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof. In some embodiments of the method in the previous three paragraphs, one or more sustained release dosage forms are provided that are two dosage forms of about 300 mg on a free base basis of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof. In some embodiments of the method in the previous three paragraphs, one or more sustained release dosage forms are provided in a dosage form of about 600 mg, on a free base basis, of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof.

[0103] In some embodiments, oral administration of one or more sustained release dosage forms to a fasting individual provides a mean time to peak plasma concentration (Tmax ) is from about 0.5 hours to about 3 hours.

[0104] In some embodiments, oral administration of one or more sustained release dosage forms to a fasting individual provides a mean time to peak plasma concentration (T max ) is at least 0.5 hours.

[0105] In some embodiments, oral administration of one or more sustained release dosage forms to a fasting individual provides mean peak plasma concentrations (C max ) mean 12-hour plasma concentration (C 12h ) is from about 5 to about 50.

[0106] In some embodiments, oral administration of one or more sustained release dosage forms to a fasting individual provides mean peak plasma concentrations (C max ) mean 12-hour plasma concentration (C 12h ) is from about 9 to about 40.

[0107] In some embodiments, oral administration of one or more sustained release dosage forms to a fasting individual provides mean peak plasma concentrations (C max ) mean 12-hour plasma concentration (C 12h ) is from about 15 to about 30.

[0108] In some embodiments, oral administration of one or more sustained release dosage forms to a fasted individual provides a mean half-life (t 1 / 2 ) is from about 1 hour to about 20 hours.

[0109] In some embodiments, oral administration of one or more sustained release dosage forms to an individual after a high fat meal provides a mean time to peak plasma concentration (T max ) is from about 1 hour to about 9 hours.

[0110] In some embodiments, oral administration of one or more sustained release dosage forms to an individual after a high fat meal provides a mean time to peak plasma concentration (T max ) is at least 1.5 hours.

[0111] In some embodiments, oral administration of one or more sustained release dosage forms to an individual after a high fat meal provides mean peak plasma concentrations (C max ) mean 12-hour plasma concentration (C 12h ) is from about 10 to about 70.

[0112] In some embodiments, oral administration of one or more sustained release dosage forms to an individual after a high fat meal provides mean peak plasma concentrations (C max ) mean 12-hour plasma concentration (C 12h ) is from about 15 to about 50.

[0113] In some embodiments, oral administration of one or more sustained release dosage forms to an individual after a high fat meal provides mean peak plasma concentrations (C max ) mean 12-hour plasma concentration (C 12h ) is from about 25 to about 45.

[0114] In some embodiments, oral administration of one or more sustained release dosage forms to an individual after a high-fat meal provides a mean half-life (t 1 / 2 ) is about 1 hour to about 7 hours.

[0115] In some embodiments, oral administration of one or more sustained release dosage forms to an individual after a high-fat meal provides a mean half-life (t 1 / 2 ) is about 2 hours to about 5 hours.

[0116] In some embodiments, the one or more sustained release dosage forms are each a tablet. In some embodiments, the one or more sustained release dosage forms are prepared by a process that includes wet granulation.

[0117] In some embodiments, the one or more sustained release dosage forms each comprise one or more hypromelloses. In some embodiments, the one or more sustained release dosage forms each comprise one or more excipients independently selected from hypromellose and microcrystalline cellulose. In some embodiments, the one or more sustained release dosage forms each comprise one or more excipients independently selected from hypromellose, microcrystalline cellulose, magnesium stearate, lactose, and lactose monohydrate. In some embodiments, the one or more sustained release dosage forms each comprise a first hypromellose characterized by having an apparent viscosity of about 80 cP to about 120 cP at 2% in water and a second hypromellose characterized by having an apparent viscosity of about 3000 cP to about 5600 cP at 2% in water.

[0118] In some embodiments, the one or more sustained release dosage forms each comprise about 10% to about 15% by weight of one or more hypromelloses. In some embodiments, the one or more sustained release dosage forms each comprise about 16% to about 22% by weight of microcrystalline cellulose. In some embodiments, the one or more sustained release dosage forms each comprise about 45% to about 55% by weight of lactose monohydrate. In some embodiments, the one or more sustained release dosage forms each comprise about 0.3% to about 0.7% by weight of magnesium stearate.

[0119] In some embodiments, the present application provides a method of treating myelofibrosis in a patient comprising orally administering to the patient a once daily dose of about 400 mg to about 600 mg, based on the free base, of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutical acceptable salt thereof. wherein the dose comprises one or more sustained release dosage forms each comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof; and the method results in a reduction in the patient's Total Symptom Score (TSS) as compared to baseline. In some embodiments, the application provides a method of treating myelofibrosis in a patient, comprising orally administering to the patient one or more sustained release dosage forms of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutical acceptable salt thereof, as a once-daily dose of about 600 mg on a free base basis; wherein the method results in a decrease in the patient's Total Symptom Score (TSS) as compared to baseline.

[0120] In some embodiments, the application provides a method of treating myelofibrosis in a patient, comprising orally administering to the patient one or more sustained release dosage forms of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutical acceptable salt thereof, as a once-daily dose of about 500 mg on a free base basis; wherein the method results in a decrease in the patient's Total Symptom Score (TSS) compared to baseline.

[0121] In some embodiments, the application provides a method of treating myelofibrosis in a patient, comprising orally administering to the patient one or more sustained release dosage forms of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutical acceptable salt thereof, as a once-daily dose of about 400 mg on a free base basis; wherein the method results in a decrease in the patient's Total Symptom Score (TSS) compared to baseline.

[0122] In some embodiments of the method in the previous three paragraphs, the one or more sustained release dosage forms are provided in six dosage forms of about 100 mg on a free base basis of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutical acceptable salt thereof. In some embodiments of the method in the previous three paragraphs, one or more sustained release dosage forms are provided in three dosage forms of about 200 mg on a free base basis of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof. In some embodiments of the method in the previous three paragraphs, one or more sustained release dosage forms are provided that are two dosage forms of about 300 mg on a free base basis of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof. In some embodiments of the method in the previous three paragraphs, one or more sustained release dosage forms are provided in a dosage form of about 600 mg, on a free base basis, of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof.

[0123] In some embodiments, "Total Symptom Score (TSS)" refers to the TSS obtained by a modified Myelofibrosis Symptom Assessment Form (MFSAF) (e.g., v3.0) electronic diary compared to baseline (wherein baseline is the patient's baseline TSS before treatment). In some embodiments, the myelofibrosis is primary myelofibrosis (PMF), post-polycythemia vera MF, or post-essential thrombocythemia MF.

[0124] The present application relates to a method for treating an autoimmune disease, cancer, a myeloproliferative disease, an inflammatory disease, a bone resorption disease, or organ transplant rejection in a patient in need thereof, comprising administering to a patient from about 400 mg or more, on a free base basis, of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutical acceptable salt thereof. to about 600 mg once a day, wherein the dose comprises one or more sustained release dosage forms each comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof; wherein the method results in a reduction in anemia.

[0125] The application also provides a method of treating an autoimmune disease, cancer, a myeloproliferative disease, an inflammatory disease, a bone resorption disease, or organ transplant rejection in a patient in need thereof, the method comprising orally administering to the patient one or more sustained release dosage forms of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof, as a once-daily dose of about 600 mg, on a free base basis; and wherein the method results in a reduction in anemia.

[0126] The application also provides a method of treating an autoimmune disease, cancer, a myeloproliferative disease, an inflammatory disease, a bone resorption disease, or organ transplant rejection in a patient in need thereof, the method comprising orally administering to the patient one or more sustained release dosage forms of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof, as a once-daily dose of about 500 mg on a free base basis; and the method results in a reduction in anemia.

[0127] The application also provides a method of treating an autoimmune disease, cancer, a myeloproliferative disease, an inflammatory disease, a bone resorption disease, or organ transplant rejection in a patient in need thereof, the method comprising orally administering to the patient one or more sustained release dosage forms of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof, as a once-daily dose of about 400 mg, on a free base basis; and wherein the method results in a reduction in anemia. In some embodiments, the one or more sustained release dosage forms are provided in six dosage forms of about 100 mg of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof, based on the free base. In some embodiments, the one or more sustained release dosage forms are provided in three dosage forms of about 200 mg of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma-ceutically acceptable salt thereof, based on the free base. In some embodiments, one or more sustained release dosage forms are provided in two dosage forms of about 300 mg on a free base basis of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof.In some embodiments, one or more sustained release dosage forms are provided in a dosage form of about 600 mg, on a free base basis, of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof.

[0128] The reduction in anemia is compared to that experienced for a twice daily dose of about 200 mg on a free base basis of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof, wherein the dose comprises one or more sustained release dosage forms each comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof.

[0129] The compounds of formula I are JAK inhibitors. A JAK1 selective inhibitor is a compound that preferentially inhibits JAK1 activity over other Janus kinases. JAK1 plays a central role in many cytokine and growth factor signaling pathways, and when dysregulated, can cause or contribute to disease states. For example, IL-6 levels are elevated in rheumatoid arthritis, a disease in which it has been shown to have deleterious effects (Fonesca, JE et al., Autoimmunity Reviews, 8:538-42, 2009). Because IL-6 signals, at least in part, through JAK1, antagonizing IL-6 directly or indirectly through inhibition of JAK1 is expected to provide clinical benefit (Guschin, D., N et al., Embo J 14:1421, 1995; Smolen, JS et al., Lancet 371:987, 2008). Furthermore, in some cancers, JAK1 is mutated, leading to constitutive and undesirable tumor cell proliferation and survival (Mullighan CG, Proc Natl Acad Sci USA.106:9414-8,2009; Flex E et al., J Exp Med.205:751-8,2008). In other autoimmune diseases and cancers, elevated systemic levels of inflammatory cytokines that activate JAK1 may contribute to the disease and / or associated symptoms. Therefore, patients with such diseases may benefit from inhibition of JAK1. Selective inhibitors of JAK1 may be effective while avoiding the unnecessary and potentially undesirable effects of inhibiting other JAK kinases.

[0130] Selective inhibitors of JAK1 may have multiple therapeutic advantages over less selective inhibitors compared to other JAK kinases. Regarding selectivity for JAK2, many important cytokines and growth factors, including erythropoietin (Epo) and thrombopoietin (Tpo), signal through JAK2 (Parganas E et al., Cell. 93:385-95, 1998). Epo is the main growth factor for the production of red blood cells, and thus, lack of Epo-dependent signaling can cause reduced red blood cell counts and anemia (Kaushansky K, NEJM 354:2034-45, 2006). Tpo, another example of a JAK2-dependent growth factor, plays a central role in controlling the proliferation and maturation of megakaryocytes, the cells that produce platelets (Kaushansky K, NEJM 354:2034-45, 2006). Thus, a reduction in Tpo signaling can reduce the number of megakaryocytes (megakaryocytopenia) and the number of circulating platelets (thrombocytopenia). This can lead to undesirable and / or uncontrollable bleeding. A reduction in inhibition of other JAKs, such as JAK3 and Tyk2, may also be desirable, since humans lacking functional versions of these kinases have been shown to suffer from a number of diseases, such as severe combined immunodeficiency or hyper-IgE syndrome (Minegishi, Y et al., Immunity 25:745-55, 2006; Macchi P et al., Nature. 377:65-8, 1995). Therefore, a JAK1 inhibitor with reduced affinity for other JAKs would have a significant advantage over less selective inhibitors in terms of reducing the side effects associated with immunosuppression, anemia, and thrombocytopenia.

[0131] Another aspect of the present invention relates to a method of treating a JAK-associated disease or disorder in an individual (e.g., a patient) by administering the sustained release dosage form of the present invention to an individual in need of such treatment. A JAK-associated disease can include any disease, disorder, or condition that is directly or indirectly linked to the expression or activity of JAK, including overexpression and / or abnormal activity levels of JAK. A JAK-associated disease can also include any disease, disorder, or condition that can be prevented, ameliorated, or treated by modulating JAK activity.

[0132] Examples of JAK-associated diseases include diseases involving the immune system, including organ transplant rejection (eg, allograft rejection and graft-versus-host disease).

[0133] Further examples of JAK-associated diseases include autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, type I diabetes, lupus, psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, myasthenia gravis, immunoglobulin nephropathy, myocarditis, autoimmune thyroid disease, chronic obstructive pulmonary disease (COPD), etc. In some embodiments, the autoimmune disease is an autoimmune bullous skin disorder such as pemphigus vulgaris (PV) or bullous pemphigoid (BP).

[0134] Further examples of JAK-associated diseases include allergic conditions such as asthma, food allergies, eczematous dermatitis, contact dermatitis, atopic dermatitis (atopic eczema), and rhinitis. Further examples of JAK-associated diseases include viral diseases such as Epstein-Barr virus (EBV), Hepatitis B, Hepatitis C, HIV, HTLV1, Varicella-Zoster virus (VZV), and Human Papillomavirus (HPV).

[0135] Further examples of JAK-associated diseases include diseases in which cartilage turnover is involved, such as gouty arthritis, suppurative or infectious arthritis, reactive arthritis, reflex sympathetic dystrophy, painful osteodystrophy, Tietze's syndrome, osteoarthropathy, endemic osteoarthritis, Mseleni's disease, Handigodu's disease, degeneration resulting from fibromyalgia, systemic lupus erythematosus, scleroderma, or ankylosing spondylitis.

[0136] Further examples of JAK-associated diseases include congenital chondrodysplasias, including hereditary chondrolysis, chondrodysplasias, and pseudochondrodysplasias (eg, microtia, anotia, and metaphyseal chondrodysplasia).

[0137] Further examples of JAK-related diseases or conditions include skin disorders such as psoriasis (e.g., plaque psoriasis), atopic dermatitis, skin rash, skin irritation, and skin sensitization (e.g., contact dermatitis or allergic contact dermatitis). For example, certain substances, including some drugs, can cause skin sensitization when applied topically. In some embodiments, simultaneous or sequential administration of at least one JAK inhibitor of the present invention with a drug that causes undesired sensitization can be useful in treating such undesired sensitization or dermatitis. In some embodiments, topical administration of at least one JAK inhibitor of the present invention treats skin disorders.

[0138] In further embodiments, the JAK-associated disease is a cancer characterized by a solid tumor (e.g., prostate cancer, renal cancer, liver cancer, pancreatic cancer, gastric cancer, breast cancer, lung cancer, head and neck cancer, thyroid cancer, glioblastoma, Kaposi's sarcoma, Castleman's disease, uterine leiomyosarcoma, melanoma, etc.), hematological cancer (e.g., lymphoma, leukemia such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) or multiple myeloma), and skin cancer such as cutaneous T-cell lymphoma (CTCL) and cutaneous B-cell lymphoma. Examples of CTCL include Sezary syndrome and mycosis fungoides.

[0139] In some embodiments, the dosage forms herein or combinations with other JAK inhibitors, such as those described in U.S. Patent Application No. 11 / 637,545, which is incorporated herein by reference in its entirety, can be used to treat inflammation-associated cancer. In some embodiments, the cancer is associated with inflammatory bowel disease. In some embodiments, the inflammatory bowel disease is ulcerative colitis. In some embodiments, the inflammatory bowel disease is Crohn's disease. In some embodiments, the inflammation-associated cancer is colitis-associated cancer. In some embodiments, the inflammation-associated cancer is colorectal cancer or colon cancer. In some embodiments, the cancer is gastric cancer, gastrointestinal carcinoid, gastrointestinal stromal tumor (GIST), adenocarcinoma, small intestine cancer, or rectal cancer.

[0140] JAK-associated diseases can further include those characterized by expression of JAK2 mutants, such as those with at least one mutation in the pseudokinase domain (e.g., JAK2V617F); JAK2 mutants with at least one mutation outside the pseudokinase domain; JAK1 mutants; JAK3 mutants; erythropoietin receptor (EPOR) mutants, or deregulated expression of CRLF2.

[0141] JAK-associated diseases can further include myeloproliferative disorders (MPDs) such as polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis with myeloid metaplasia (MMM), primary myelofibrosis (PMF), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), hypereosinophilic syndrome (HES), and systemic mastocytosis (SMCD). In some embodiments, the myeloproliferative disorder is myelofibrosis (e.g., primary myelofibrosis (PMF) or polycythemia vera / post-essential thrombocythemia myelofibrosis (Post-PV / Post-ET MF)). In some embodiments, the myeloproliferative disorder is myelofibrosis after essential thrombocythemia (Post-ET). In some embodiments, the myeloproliferative disorder is myelofibrosis after polycythemia vera (Post-PV MF).

[0142] In some embodiments, the dosage forms described herein can be used to treat pulmonary arterial hypertension.

[0143] The present invention further provides a method for treating the skin side effects of other medicines by administering the dosage form of the present invention.For example, many medicines cause unwanted allergic reactions, which may manifest as acne-like rashes or related dermatitis.Examples of medicines with such unwanted side effects include anticancer drugs such as gefitinib, cetuximab, erlotinib, etc.The dosage form of the present invention can be administered systemically in combination (e.g., simultaneously or sequentially) with medicines with unwanted skin side effects.

[0144] Further JAK-related diseases include inflammation and inflammatory diseases.Examples of inflammatory diseases include sarcoidosis, ocular inflammatory diseases (e.g., iritis, uveitis, scleritis, conjunctivitis, or related diseases), respiratory tract inflammatory diseases (e.g., inflammatory diseases of the upper respiratory tract, including nose and paranasal sinuses, such as rhinitis or sinusitis, or inflammatory diseases of the lower respiratory tract, including bronchitis, chronic obstructive pulmonary disease, etc.), inflammatory myopathy, such as myocarditis, and other inflammatory diseases.In some embodiments, the ocular inflammatory disease is blepharitis.

[0145] The dosage forms described herein can further be used to treat diseases or conditions associated with ischemia-reperfusion injury or inflammatory ischemic events such as stroke or cardiac arrest. The dosage forms described herein can further be used to treat endotoxin-induced disease states (e.g., complications after bypass surgery or chronic endotoxin conditions contributing to chronic heart failure). The dosage forms described herein can further be used to treat anorexia, cachexia, fatigue, such as those caused by or associated with cancer. The dosage forms described herein can further be used to treat restenosis, sclerodermatitis, fibrosis. The dosage forms described herein can further be used to treat conditions associated with hypoxia or astrogliosis, such as diabetic retinopathy, cancer, or neurodegeneration. See, e.g., Dudley, AC et al., Biochem. J. 2005, 390(Pt2):427-36 and Sriram, K et al., J. Biol. Chem. 2004, 279(19):19936-47. Epub 2004 Mar 2, both of which are incorporated by reference in their entireties. The JAK inhibitors described herein can be used to treat Alzheimer's disease.

[0146] The dosage forms described herein can further be used to treat other inflammatory diseases, such as systemic inflammatory response syndrome (SIRS) and septic shock.

[0147] The dosage forms described herein can further be used to treat gout and increased size of the prostate due to, for example, benign prostatic hyperplasia or benign prostatic hyperplasia.

[0148] Further, JAK-associated diseases include bone resorption diseases such as osteoporosis, osteoarthritis, etc. Bone resorption may also be associated with other conditions such as hormonal imbalance and / or hormone therapy, autoimmune diseases (e.g., bone sarcoidosis), or cancer (e.g., myeloma). The reduction in bone resorption resulting from the compounds of formula I may be about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90%.

[0149] In some embodiments, the dosage forms described herein can further be used to treat dry eye disorders. As used herein, "dry eye disorder" is intended to encompass disease states summarized in the recent official report of the Dry Eye Workshop (DEWS), which defines dry eye as "a multifactorial disorder of the tears and ocular surface that results in symptoms such as discomfort, visual disturbance, and tear film instability, with potential damage to the ocular surface. It is associated with increased tear film osmolality and inflammation of the ocular surface." Lemp, "The Definition and Classification of Dry Eye Disease: Report of the Definition and Classification Subcommittee of the International Dry Eye Workshop", The Ocular Surface, 5(2), 75-92 April 2007, which is incorporated herein by reference in its entirety. In some embodiments, the dry eye disorder is selected from aqueous tear deficient dry eye (ADDE) or evaporative dry eye disorder, or a suitable combination thereof. In some embodiments, the dry eye disorder is Sjogren's syndrome dry eye (SSDE). In some embodiments, the dry eye disorder is non-Sjogren's syndrome dry eye (NSSDE).

[0150] In further aspects, the present invention provides a method of treating conjunctivitis, uveitis (including chronic uveitis), choroiditis, retinitis, cyclitis, scleritis, episcleritis, or iritis; treating inflammation or pain associated with corneal transplantation, LASIK (laser in situ keratomileusis), laser photorefractive keratectomy, or LASEK (laser epithelial keratomileusis); inhibiting loss of vision associated with corneal transplantation, LASIK, laser photorefractive keratectomy, or LASEK; or inhibiting transplant rejection in a patient in need thereof comprising administering to said patient a dosage form of the present invention.

[0151] Additionally, the dosage forms of the present invention, or combinations with other JAK inhibitors, such as those reported in U.S. Patent Application No. 11 / 637,545, which is incorporated by reference in its entirety, can be used to treat respiratory dysfunction or failure associated with viral infections such as influenza and SARS.

[0152] In some embodiments, the present invention provides a dosage form described in any of the embodiments herein for use in a method of treating any of the diseases or disorders described herein. In some embodiments, the present invention provides the use of a dosage form described in any of the embodiments herein for the preparation of a medicament for use in a method of treating any of the diseases or disorders described herein.

[0153] In some embodiments, the present invention provides a dosage form described herein, or a pharma- ceutically acceptable salt thereof, for use in a method of modulating JAK1. In some embodiments, the present invention also provides the use of a dosage form described herein, or a pharma- ceutically acceptable salt thereof, for the preparation of a medicament for use in a method of modulating JAK1.

[0154] As used herein, the term "individual" refers to a human. In some embodiments, the human is an adult subject.

[0155] As used herein, the term "treating" or "treatment" refers to one or more of: (1) inhibiting a disease, e.g., inhibiting a disease, condition, or disorder (i.e., halting further progression of the pathology and / or symptomology) in an individual experiencing or exhibiting the pathology or symptomology of the disease, condition, or disorder; and (2) ameliorating a disease, condition, or disorder (i.e., reversing the pathology and / or symptomology) in an individual experiencing or exhibiting the pathology or symptomology of the disease, condition, or disorder, such as reducing the severity of the disease.

[0156] Combination therapy One or more additional pharmaceutical agents, such as, for example, chemotherapeutic agents, anti-inflammatory agents, steroids, immunosuppressants, and the like, as well as Bcr-Abl, Flt-3, RAF, and FAK kinase inhibitors, such as those described in WO2006 / 056399, which is incorporated herein by reference in its entirety, or other agents, can be used in combination with the dosage forms described in the present invention for the treatment of a JAK-associated disease, disorder, or condition. The one or more additional pharmaceutical agents can be administered to the patient simultaneously or sequentially.

[0157] Examples of chemotherapeutic agents include proteosome inhibitors (eg, bortezomib), thalidomide, revlimid, and DNA damaging agents such as melphalan, doxorubicin, cyclophosphamide, vincristine, etoposide, carmustine, and the like.

[0158] Examples of steroids include corticosteroids such as dexamethasone or prednisone.

[0159] Examples of Bcr-Abl inhibitors include the genera and species of compounds disclosed in U.S. Pat. No. 5,521,184, WO 04 / 005281, and U.S. Patent Application No. 60 / 578,491, all of which are incorporated herein by reference in their entirety, and pharma- ceutical acceptable salts thereof.

[0160] Examples of suitable Flt-3 inhibitors include the compounds disclosed in WO03 / 037347, WO03 / 099771, and WO04 / 046120, all of which are incorporated by reference in their entirety, and pharma- ceutically acceptable salts thereof.

[0161] Examples of suitable RAF inhibitors include the compounds disclosed in WO00 / 09495 and WO05 / 028444, both of which are incorporated herein by reference in their entirety, and pharma- ceutically acceptable salts thereof.

[0162] Examples of suitable FAK inhibitors include those compounds disclosed in WO04 / 080980, WO04 / 056786, WO03 / 024967, WO01 / 064655, WO00 / 053595, and WO01 / 014402, all of which are incorporated by reference in their entirety, and pharma- ceutically acceptable salts thereof.

[0163] In some embodiments, one or more of the dosage forms of the present invention can be used in combination with one or more other kinase inhibitors, including imatinib, particularly to treat patients who are resistant to imatinib or other kinase inhibitors.

[0164] In some embodiments, one or more dosage forms of the present invention can be used in combination with chemotherapeutic agents in the treatment of cancers such as multiple myeloma, and can improve treatment response compared to the response to the chemotherapeutic agent alone without exacerbating its toxic effects. Examples of additional pharmaceutical agents used in the treatment of multiple myeloma can include, but are not limited to, for example, melphalan, melphalan + prednisone [MP], doxorubicin, dexamethasone, and Velcade (bortezomib). Further additional agents used in the treatment of multiple myeloma include Bcr-Abl, Flt-3, RAF, and FAK kinase inhibitors. Combining the dosage forms of the present invention with additional agents desirably results in additive or synergistic effects. Furthermore, the resistance of multiple myeloma cells to agents such as dexamethasone can be reversed upon treatment with the dosage forms of the present invention. The agents can be combined with the compounds of the present invention in a single dosage form or sequential dosage form, or the agents can be administered simultaneously or sequentially as separate dosage forms.

[0165] In some embodiments, a corticosteroid such as dexamethasone is administered to a patient in combination with a dosage form of the present invention, where the dexamethasone is administered intermittently rather than continuously.

[0166] In some further embodiments, a combination of one or more JAK inhibitors of the present invention and other therapeutic agents can be administered to a patient before, during, and / or after bone marrow or stem cell transplantation.

[0167] In some embodiments, the additional therapeutic agent is fluocinolone acetonide (Retisert®), or rimexolone (AL-2178, Vexol, Alcon).

[0168] In some embodiments, the additional therapeutic agent is cyclosporine (Restasis®).

[0169] In some embodiments, the additional therapeutic agent is a corticosteroid. In some embodiments, the corticosteroid is triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone, or flumetholone.

[0170] In some embodiments, the additional therapeutic agent is Dehydrex™ (Holles Labs), civamide (Opko), sodium hyaluronate (Vismed, Lantibio / TRB Chemedia), cyclosporine (ST-603, Sirion Therapeutics), ARG101(T) (testosterone, Argentis), AGR1012(P) (Argentis), ecabet sodium (Senju Pharmaceutical-Ista), gefarnate (Santen Pharmaceuticals), 15-(s)-hydroxyeicosatetraenoic acid (15(S)-HETE), seviremine, doxycycline (ALTY-0501, Alacrity), minocycline, iDestrin™ (NP50301, Nascent Pharmaceuticals), cyclosporine A (Nova22007, Novagali), oxytetracycline (Duramycin, MOLI1901, Lantibio), CF101(2S,3S,4R,5R)-3,4-Dihydroxy-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]-N-methyl-oxolane-2-carbamyl, Can-Fite Biopharma), voclosporin (LX212 or LX214, Lux Biosciences), ARG103 (Agentis), RX-10045 (synthetic resolvin analog, Resolvyx), DYN15 (Dyanmis Therapeutics), rivoglitazone (DE011, Daiichi Sankyo), TB4 (RegeneRx), OPH-01 (Ophtalmis Monaco), PCS101 (Pericor Science), REV1-31 (Evolutec), lacritin (Senju Pharmaceutical), rebamipide (Otsuka Pharmaceutical-Novartis), OT-551 (Othera), PAI-2 (University of Pennsylvania and Temple University) University), pilocarpine, tacrolimus, pimecrolimus (AMS981, Novartis), loteprednol etabonate, rituximab, diquafosol tetrasodium (INS365, Inspire), KLS-0611 (Kissei Pharmaceutical Co., Ltd.), dehydroepiandrosterone, anakinra, efalizumab, mycophenolate sodium, etanercept (Embrel®), hydroxychloroquine, NGX267 (TorreyPines Therapeutics), Actemra, gemcitabine, oxaliplatin, L-asparaginase, or thalidomide.

[0171] In some embodiments, the additional therapeutic agent is an antiangiogenic agent, a cholinergic agent, a TRP-1 receptor modulator, a calcium channel blocker, a mucin secretagogue, a MUC1 stimulator, a calcineurin inhibitor, a corticosteroid, a P2Y2 receptor agonist, a muscarinic receptor agonist, an mTOR inhibitor, another JAK inhibitor, a Bcr-Abl kinase inhibitor, an Flt-3 kinase inhibitor, a RAF kinase inhibitor, and a FAK kinase inhibitor, such as those described in WO2006 / 056399, which is incorporated herein by reference in its entirety.In some embodiments, the additional therapeutic agent is a tetracycline derivative (e.g., minocycline or doxycline).In some embodiments, the additional therapeutic agent binds to FKBP12.

[0172] In some embodiments, the additional therapeutic agent is an alkylating or DNA crosslinking agent; antimetabolite / demethylating agent (e.g., 5-fluorouracil, capecitabine, or azacitidine); anti-hormonal therapy (e.g., hormone receptor antagonists, SERMs, or aromatase inhibitors); mitotic inhibitors (e.g., vincristine or paclitaxel); topoisomerase (I or II) inhibitors (e.g., mitoxantrone and irinotecan); apoptosis inducers (e.g., ABT-737). ; nucleic acid therapy (e.g., antisense or RNAi); nuclear receptor ligands (e.g., agonists and / or antagonists: all-trans retinoic acid or bexarotene); epigenetic targeted agents such as histone deacetylase inhibitors (e.g., vorinostat), hypomethylating agents (e.g., decitabine); modulators of protein stability such as Hsp90 inhibitors, ubiquitin and / or ubiquitin-like conjugating or unconjugating molecules; or EGFR inhibitors (erlotinib).

[0173] In some embodiments, the additional therapeutic agent(s) are demulcent eye drops (also known as "artificial tears"), including but not limited to compositions containing polyvinyl alcohol, hydroxypropylmethylcellulose, glycerin, polyethylene glycol (e.g., PEG 400), or carboxymethylcellulose. Artificial tears can help treat dry eye by compensating for the reduced wetting and lubricating ability of the tear film. In some embodiments, the additional therapeutic agent is a mucolytic agent, such as N-acetyl-cysteine, which can decrease the viscosity of the tear film by interacting with mucoproteins.

[0174] In some embodiments, the additional therapeutic agent includes antibiotics, antivirals, antifungals, anesthetics, anti-inflammatory drugs, including steroidal and nonsteroidal anti-inflammatory drugs, and anti-allergy drugs. Examples of suitable drugs include aminoglycosides, such as amikacin, gentamicin, tobramycin, streptomycin, netilmicin, and kanamycin; fluoroquinolones, such as ciprofloxacin, norfloxacin, ofloxacin, trovafloxacin, lomefloxacin, levofloxacin, and enoxacin; naphthyridine; sulfonamides; polymyxins; chloramphenicol; neomycin; paramomycin; colistimethate; bacitracin; vancomycin; cyclosporine ... mycin; tetracyclines; rifampin and its derivatives ("rifampins"); cycloserine; beta-lactams; cephalosporins; amphotericins; fluconazole; flucytosine; natamycin; miconazole; ketoconazole; corticosteroids; diclofenac; flurbiprofen; ketorolac; suprofen; cromolyn; lodoxamide; levocabastine; naphazoline; antazoline; pheniramine; or azalide antibiotics.

[0175] It is to be further appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment (as if the embodiments herein were recited as multiple dependent claims). EXAMPLES

[0176] Example 1. Preparation of sustained release formulation Extended release tablets were prepared with excipients in the amounts shown in the table below: Protocol A was used for SR1 tablets, Protocol B was used for SR2 tablets, Protocol C was used for SR3 tablets and 25 mg SR tablets, and Protocol D was used for SR4 tablets.

[0177] Protocol A: Step 1. Individually screen the adipate salt of the compound of Formula I, microcrystalline cellulose, hypromellose (Methocel K100 LV and Methocel K4M), and lactose monohydrate. Step 2. Transfer the screened material from step 1 into a suitable blender and mix. Step 3. The mixture from step 2 is transferred to a suitable granulator and mixed. Step 4. Add purified water while mixing. Step 5. The granules from step 4 are transferred into a suitable dryer and dried until the LOD is less than 3%. Step 6. Screen the granules obtained in step 5. Step 7. Blend the screened magnesium stearate with the granules from Step 6 in a suitable blender. Step 8. Compress the final blend of Step 7 on a suitable rotary tablet press.

[0178] Protocol B: Step 1. Screen the adipate salt of the compound of formula I, microcrystalline cellulose, hypromellose and pregelatinized starch individually. Step 2. Transfer the screened material from step 1 into a suitable blender and mix. Step 3. The mixture from step 2 is transferred to a suitable granulator and mixed. Step 4. Add purified water while mixing. Step 5. The granules from step 4 are transferred into a suitable dryer and dried until the LOD is less than 3%. Step 6. Screen the granules obtained in step 5. Step 7. Polyox, butylated hydroxytoluene and colloidal silicon dioxide were screened individually. Step 8. Transfer the granules from step 6 and the material from step 7 into a suitable blender and mix. Step 9. Add the screened magnesium stearate to the materials from Step 8 and continue blending. Step 10. Compress the final blend of Step 9 on a suitable rotary tablet press.

[0179] Protocol C: Step 1. Lactose monohydrate, the adipate salt of the compound of formula I, microcrystalline cellulose and hypromellose are individually screened through suitable sieves. Step 2. Transfer the screened material from step 1 into a suitable blender and mix. Step 3. The mixture from step 2 is transferred to a suitable granulator and mixed. Step 4. Add purified water while mixing. Step 5. Screen the wet granules through a suitable sieve. Step 6. The granules from step 5 are transferred into a suitable dryer and dried until the LOD is less than 3%. Step 7. Mill the granules obtained in step 6. Step 8. Blend the screened magnesium stearate with the granules from Step 7 in a suitable blender. Step 9. Compress the final blend of Step 8 on a suitable rotary tablet press.

[0180] Protocol D: Step 1. Pregelatinized starch, the adipate salt of the compound of formula I, hypromellose, and a portion of the required microcrystalline cellulose are individually screened through a suitable sieve. Step 2. Transfer the screened material from step 1 into a suitable blender and mix. Step 3. The mixture from step 2 is transferred to a suitable granulator and mixed. Step 4. Add purified water while mixing. Step 5. Screen the wet granules through a suitable sieve. Step 6. The granules from step 5 are transferred into a suitable dryer and dried until the LOD is less than 3%. Step 7. Mill the granules obtained in step 6. Step 8. Screen the remaining portion of the microcrystalline cellulose and half of the sodium bicarbonate. Step 9. The milled granules from step 7 and the screened material from step 8 are transferred to a suitable blender and mixed. Step 10. Screen the remaining portion of sodium bicarbonate and mix with the mixture from step 9. Step 11. Screen the magnesium stearate and mix with the mixture from step 10. Step 12. Compress the final blend of Step 11 on a suitable rotary tablet press.

[0181] SR1: Composition of 100mg sustained release tablets [Table 1] a The conversion factor for adipate to the free base is 0.7911. bAdded after granulation cRemoved during processing

[0182] SR2: Composition of 100mg sustained release tablets [Table 2] a The conversion factor for adipate to the free base is 0.7911. bAdded after granulation cRemoved during processing

[0183] SR3(100mg): Composition of 100mg sustained release tablet [Table 3] a The conversion factor for adipate to the free base is 0.7911. bAdded after granulation cRemoved during processing

[0184] SR4: Composition of 100mg sustained release tablets [Table 4] a The conversion factor for adipate to the free base is 0.7911. bAdded after granulation cRemoved during processing d Partially added before granulation, partly added after granulation

[0185] 25mg SR: Composition of 25mg sustained release tablet [Table 5] a The conversion factor for adipate to the free base is 0.7911. bAdded after granulation cRemoved during processing

[0186] Example 2. Preparation of an IR formulation of a compound of formula I The IR formulation used in the study of Example 3 was prepared as a 50 mg capsule having the composition shown in the table below according to Protocol E below.

[0187] Protocol E: Step 1. Premix the required amount of the adipate salt of the compound of formula I and an approximately equal amount of silicified microcrystalline cellulose (SMCC). Step 2. Pass the mixture from step 1 through a suitable sieve (e.g., 40 mesh). Step 3. Screen the remaining SMCCs through a screen identical to that used in step 2. Step 4. Mix the screened SMCC from step 3 with the mixture from step 2 in a suitable blender (eg, Turbula blender) for approximately 5 minutes. Step 5. Fill the mixture into capsules to the desired fill weight. [Table 6] * The adipate salt of the compound of formula I has a salt conversion factor of 0.7911

[0188] Example 3. Relative bioavailability study of sustained release dosage forms A total of 72 healthy adult subjects were enrolled in 6 cohorts (12 subjects per cohort) and randomized to treatment sequences within each cohort according to a randomization schedule. All treatments were single doses of the compound of formula I. There was a 7-day washout period between treatment periods.

[0189] SR1, SR2, SR3, and SR4 formulations were evaluated in Cohort 1, Cohort 2, Cohort 3, and Cohort 4, respectively (see Example 1 for SR1, SR2, SR3, SR4, and 25 mg SR tablets used in this study). Subjects received IR and SR treatments according to a three-period crossover study: Treatment A: 300 mg (6 x 50 mg capsules) of an IR formulation of the compound of Formula I was administered orally after an overnight fast of at least 10 hours. Treatment B: 300 mg (3 x 100 mg tablets) of the SR formulation of the compound of formula I was administered orally after an overnight fast of at least 10 hours. Treatment C: 300 mg (3×100 mg tablets) of the SR formulation of the compound of Formula I was administered orally after a high fat meal.

[0190] Subjects in Cohort 5 received the following treatments in a two-period crossover study: Treatment A: 300 mg (3 x 100 mg tablets of the compound of Formula I) SR3 was administered orally after an overnight fast of at least 10 hours. Treatment B: 300 mg (3 x 100 mg tablets of the compound of Formula I) SR3 was administered orally after a moderate fat meal.

[0191] Subjects in Cohort 6 received the following treatments in a three-period crossover study: Treatment A: 50 mg (2×25 mg tablets of the compound of Formula I (25 mg SR tablets from Example 1)) was administered orally after an overnight fast of at least 10 hours. Treatment B: 50 mg (2×25 mg tablets of the compound of Formula I (25 mg SR tablets from Example 1)) administered orally after a high fat meal. Treatment C: 100 mg (1 x 100 mg tablet) SR3 was administered orally after an overnight fast of at least 10 hours.

[0192] Blood samples for determination of plasma concentrations of the compound of Formula I were collected at 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, and 48 hours post-dose using lavender-capped (K2EDTA) Vacutainer® blood collection tubes.

[0193] Plasma samples were assayed by a validated GLP, LC / MS / MS method with a linear range of 5.0-5000 nM. Table 1 summarizes the accuracy and precision (CV%) of the assay quality control samples during the analysis of plasma samples from this study.

[0194] [Table 7] CV% = percent coefficient of variation; QC = quality control; Theo = theoretical or nominal concentration

[0195] For PK analyses, actual sample collection times were used. For any samples missing actual collection times, scheduled times were used, provided there were no protocol deviations noted for the collection of these samples.

[0196] Standard noncompartmental PK analysis methods were used to analyze data on plasma concentrations of the compound of formula using Phoenix WinNonlin version 6.0 (Pharsight Corporation, Mountain View, CA). max and T max was taken directly from the observed plasma concentration data. The terminal-phase disposition rate constant (λ z ) was estimated using log-linear regression of the concentration data during the terminal elimination phase, and t 1 / 2 ln(2) / λ z The AUC was estimated using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations. 0-t Estimate the total AUC 0-∞ AUC 0-t +C t / λ z Oral dose clearance (CL / F) was calculated as Dose / AUC0-∞ The terminal-phase volume of distribution (V z / F) is calculated by Dose / [AUC 0-∞ * λ z ] was estimated.

[0197] Log-transformed C max and AUC values ​​(after dose normalization when doses differed) were compared between fasted and fed dosing treatments, and between SR and IR dosing treatments using a crossover ANOVA test (fixed factors = treatment, sequence, and time; random effect = subject (sequence)). max The adjusted geometric mean ratios (baseline = fasting administration of SR or IR) of AUC and the corresponding 90% confidence intervals (CI) were determined. In addition, the high-fat meal significantly reduced AUC 0-∞ Correlations between the observed food effect on and the relative bioavailability of the SR formulation (relative to the IR capsule) were examined by quantile plots using data from all subjects who completed treatments A, B, and C in cohorts 1 to 4. Statistical analyses were performed using Phoenix WinNonlin version 6.0.

[0198] Figure 1 represents the plasma concentrations (mean ± SE) of the compound of formula I in subjects from cohorts 1 to 4 after treatment A (300 mg IR administered in the fasted state), treatment B (300 mg SR administered in the fasted state), and treatment C (300 mg SR administered with a high fat meal). Figure 2 compares the effect of high and medium fat meals on the mean PK profile after a single dose of 300 mg (3 x 100 mg) of the compound of formula I SR3 tablet. Figure 3 represents the plasma concentrations (mean ± SE) of the compound of formula I in subjects from cohort 6 after treatment A (2 x 25 mg SR tablets administered in the fasted state), treatment B (2 x 25 mg SR tablets administered with a high fat meal), and treatment C (1 x 100 mg SR3 administered in the fasted state).

[0199] Tables 2A, 2B, 3A, and 3B summarize the mean PK parameters, relative bioavailability (baseline=IR capsule) and food effect (high fat meal) for the 100 mg strength SR1-SR4 tablets for subjects in cohorts 1 through 4. Tables 4A and 4B summarize the mean PK parameters, and food effect (medium fat meal) for the 100 mg strength SR3 tablet for subjects in cohort 5. Tables 5A and 5B summarize the mean PK parameters, dose-normalized relative bioavailability (baseline=100 mg SR3 tablet), and food effect (high fat meal) for the 25 mg SR tablet for subjects in cohort 6.

[0200] [Table 8]

[0201] [Table 9]

[0202] [Table 10] Median values ​​(90% confidence intervals) are reported T max Except for , PK parameter values ​​are means ± SD and geometric means.

[0203] [Table 11] Median values ​​(90% confidence intervals) are reported T max Except for , PK parameter values ​​are means ± SD and geometric means.

[0204] [Table 12] Median values ​​(90% confidence intervals) are reported T max Except for , pharmacokinetic parameter values ​​are means ± SD and geometric means.

[0205] [Table 13] Median values ​​(90% confidence intervals) are reported T max Except for , pharmacokinetic parameter values ​​are means ± SD and geometric means.

[0206] [Table 14] NC = significant number of within-subject mismatches between treatments T last Not calculated for NR = significant number of C 12h Not reported because values ​​were below the limit of quantification (BQL). Median values ​​(90% confidence intervals) are reported T max Except for , PK parameter values ​​are means ± SD and geometric means. i) Statistical comparisons were dose-normalized.

[0207] [Table 15] NC = significant number of within-subject mismatches between treatments T last Not calculated for; NR = significant number of C 12h Not reported because values ​​were below the limit of quantification (BQL). Median values ​​(90% confidence intervals) are reported T max Except for , PK parameter values ​​are means ± SD and geometric means. i) Statistical comparisons were dose-normalized.

[0208] The mean PK profiles following administration of a single dose of the 300 mg IR capsule under fasting conditions were similar among subjects in cohorts 1 through 4 (Figure 1). Compared with the IR formulation, the observed plasma T max The median was moderately extended (0.3 to 1.5 hours), and the mean C max The values ​​were significantly decreased (geometric mean C max The upper limit of the 90% CI for the ratio was less than 30%), indicating that the absorption rate of the compound of formula I was reduced in the SR tablet.1 / 2 was significantly longer for SR1-SR4, ranging from 7.3 to 11 hours, compared to approximately 2 hours for the IR capsule, indicating that the systemic elimination of the compound of formula I appears to be rate-limited by its absorption, which is sustained in the terminal elimination phase. max The lower and disappearance of t 1 / 2 As the length of max / C 12h The ratios were significantly lower in the SR tablets compared to the IR capsules in the same subjects. max / C 12h The ratios were 11.6-fold, 8.6-fold, 19.3-fold, and 8.9-fold for the SR1, SR2, SR3, and SR4 tablets, respectively, compared to 112-fold to 162-fold for the IR capsule administered in the fasted state.

[0209] When administered in the fasted state, the four SR tablets showed reduced relative bioavailability compared to the IR capsules administered to the same subjects. max The geometric mean proportions (%) (90% CI) of AUC were 14.2% (11.4%-17.5%), 8.9% (6.7%-11.9%), 22.3% (17.4%-28.6%), and 9.0% (6.8%-11.9%) for SR1, SR2, SR3, and SR4, respectively. 0-∞ The geometric mean percentages (90% CI) of were 36.1% (33.3%-39.2%), 26.0% (21.6%-31.3%), 47.5% (41.9%-53.9%), and 28.5% (23.2%-35.1%) for SR1, SR2, SR3, and SR4, respectively. SR3 and SR1 demonstrated the best and second best relative bioavailability, respectively, among the SR formulations tested.

[0210] Inter-subject variability, as measured by percent coefficient of variation (CV%) in plasma exposure, dosed in the fasted state, was significantly higher for the gastrointestinal retained formulation SR4, but was comparable among the three regular SR tablets designed for release in the intestine. The inter-subject CV% for the 100 mg SR1 tablet was C max and AUC0-∞ The intersubject CV% for the 100 mg SR2 tablet was 39% and 33%, respectively. max and AUC 0-∞ The intersubject CV% for the 100 mg SR3 tablet was 50% and 37%, respectively. max and AUC 0-∞ The intersubject CV% for the 100 mg SR4 tablet was 43% and 29%, respectively. max and AUC 0-∞ For all subjects (n=59) in cohorts 1-5 who received 300 mg IR in the fasting state, the between-subject CV% was 83% and 73%, respectively. max and AUC 0-∞ The CV% for SR1, SR2, and SR3 were 49% and 39%, respectively, which were comparable to the CV% observed for SR1, SR2, and SR3.

[0211] A positive food effect was observed for all SR formulations tested at the 300 mg (3 × 100 mg) dose level. When administered after a high-fat meal, the geometric mean C max and AUC 0-∞ Values ​​increased by 88% and 81% for SR1, respectively; 158% and 118% for SR2, respectively; 91% and 45% for SR3, respectively; and 93% and 115% for SR4, respectively. The food effect was moderate with a medium fat meal compared to a high fat meal, as shown by the data for SR3 in cohort 5. For SR3, C max and AUC 0-∞ values ​​increased by 46% and 17%, respectively. Administration with food did not significantly alter the inter-subject CV% in plasma exposure of the compound of Formula I for SR1, SR2, and SR3, SR formulations designed for intestinal release. For SR4, the gastrointestinal retained SR formulation, the inter-subject CV% in plasma exposure appeared to be significantly decreased when given with a high fat meal.

[0212] The study also investigated the dose-normalized relative bioavailability of the 25 mg SR tablet relative to the 100 mg SR3 tablet. For subjects in Cohort 6, the dose-normalized C of 2 × 25 mg SR3 treatments was 1 × 100 mg SR3 administered in the fasting state vs. max and AUC 0-∞ The geometric mean percentages were 59% and 66%, respectively. However, due to the supralinear dose-exposure relationship of the compound of formula I, the relative bioavailability of the 25 mg SR tablet may be underestimated. For the 2×25 mg SR dose, a high-fat meal significantly increased the bioavailability of the compound of formula I. max and AUC 0-∞ by 60% and 58%, respectively.

[0213] The observed apparent disappearance of t for the four SR formulations evaluated 1 / 2 are equivalent, and C obtained from a single dose administered in the fasting state max / C 12h (used as a surrogate for the P / T ratio obtained from twice-daily dosing) was similar between SR1, SR2, and SR4 (approximately 10-fold) and moderately high for SR3 (approximately 20-fold). Overall, all four SR formulations demonstrated significantly flatter PK profiles compared to the IR capsule, fulfilling an important objective for sustained release. The bioavailability of an orally administered drug product can be defined by the rate and extent of drug absorption into the systemic circulation. Reduction in the rate of drug absorption due to limited rate of drug release from the drug product is a design requirement for sustained release formulations. Therefore, for the SR formulations, the plasma AUC 0-∞ The extent of absorption of the compound of formula I, as measured by β-glucose dissolution assay, is used as the primary endpoint for evaluating the relative bioavailability. Thus, the average relative bioavailability was similar between SR2 (26%) and SR4 (29%), which was slightly lower than SR1 (36%). The best relative bioavailability was observed for SR3 (48%). The results are consistent with the in vitro dissolution profile obtained prior to conducting this study.

[0214] A clear inverse correlation was observed between food effect and relative bioavailability for the SR formulation. On average, when administered with a high-fat meal, AUC 0-∞ Food effect, as measured by the increase in AUC, was greatest for SR2 (118%) and SR4 (115%), which was lower than that for SR1 (81%). The least food effect was observed for SR3 (45%). This correlation was also evident when data from all subjects were combined into one. A quantile plot using the combined individual data (separated into 5 bins with 9 subjects per bin) shows that food effect was more pronounced (>2-fold increase in AUC) for subjects with relative bioavailability less than 35%, regardless of formulation. Food effect was moderate (approximately 50% or less increase in AUC) for subjects with relative bioavailability greater than 40%, regardless of formulation. SR3 achieved a mean relative bioavailability of 48%, which appears to be associated with a moderate food effect. Indeed, when SR3 tablets (3×100 mg) were administered with a moderate fat meal (more typical of daily meals), the geometric mean AUC 0-∞ The observed increase in was only 17%, indicating that this formulation can be administered without a medium or low fat meal. In terms of avoiding significant food effects, SR3 is superior to other formulations.

[0215] Example 4. Phase 2a Clinical Results in Patients with Active Rheumatoid Arthritis (RA) The first 28 days of the study were conducted to select prospective doses to guide dose selection for the second, 3-month part of the study. In the second part of the study, treatment was 84 days, randomized, double-blind, and placebo-controlled (sponsor-blinded). Sixty subjects were randomized using the same population as in Part 1: a single cohort, 5 parallel treatment arms, 12 subjects each: 100 mg SR3 tablets twice daily; 300 mg (3 x 100 mg SR3 tablets) once daily; 200 mg (2 x 100 mg SR3 tablets) twice daily; 600 mg (6 x 100 mg SR3 tablets) once daily; and placebo. Interim data were submitted to the ACR (American College of Rheumatology) 2013 (n=40 subjects who completed 84 days). ACR scores at 3 months are shown in Table 6. The ACR scores for 600 mg once daily are unprecedented compared to other JAK inhibitors approved for the treatment of RA. For example, products approved for tofacitinib citrate (5 mg twice daily) showed much lower ACR scores at 3 months: 59% (ACR20), 31% (ACR50), and 15% (ACR70) (XELJANZ®-Tofacitinib Citrate Tablets-labeled in Table 5).

[0216] [Table 16]

[0217] The percent change from baseline for hemoglobin was also examined for each dosing regimen (Figure 4). As can be seen in Figure 4, the 200mg twice daily dose showed a drop from baseline compared to the other doses, which tended to remain near placebo levels. For example, the 600mg once daily dose did not show the same downward trend as the twice daily doses. However, as can be seen in Table 6, once daily dosing (600mg once daily) did not compromise efficacy compared to the twice daily dose. This indicates that once daily dosing (such as 600mg once daily) may achieve maximum efficacy without inducing side effects such as anemia. As shown in Figure 4 and Table 6, the 600mg once daily dose has a strong effect with a small change in hemoglobin levels.

[0218] This efficacy / side effect profile may be due to the once-daily dose achieving maximum JAK1 signaling (leading to efficacy) with low JAK2 inhibition at trough, since JAK2 signaling is linked to hematopoiesis. This hypothesis is supported by the PK-derived JAK1 (IL-6) and JAK2 (TPO) inhibition data for the compound of formula at various doses (Table 7). Specifically, the 600mg once-daily dose showed similar mean IL-6 inhibition to the 200mg twice-daily and 400mg twice-daily doses (61% vs. 64% and 69%), but lower trough TPO inhibition compared to the 200mg twice-daily and 400mg twice-daily doses (4% vs. 13% and 16%). The trough IL-6 inhibition of the 600 mg once daily dose was also lower than that of the 200 mg twice daily and 400 mg twice daily doses, suggesting that there may be a reduction in infections from the once daily dose.

[0219] [Table 17]

[0220] Example 5. Clinical outcomes in patients with plaque psoriasis A double-blind (sponsor-unblinded), randomized, placebo-controlled study was conducted in approximately 48 subjects treated over 28 days. Eligibility requirements included: active plaque psoriasis for at least 6 months at screening; plaque psoriasis covering 5% or more of body surface area (BSA); Psoriasis Area and Severity Index (PASI) score 5 or greater; Static Physician Global Assessment Index (sPGA) score 3 or greater; inadequate response to topical therapy; an innovative design allowing rapid escalation between doses, with conservative safety assessments. Four staggered dose arms of 12 subjects each (9 actives and 3 PBO) escalating from 100 mg once daily to 200 mg once daily to 200 mg twice daily to 600 mg once daily. Once the fourth subject (triple-active 1 PBO group) completed 28 days of treatment without grade 3 or higher adverse events, the next group of 12 subjects began treatment at the next higher dose; the first group was randomized to 60 subjects with moderate to severe psoriasis while the first 4 subjects of this group were treated for 28 days. There were five treatment groups: placebo, 100 mg once daily, 200 mg once daily, 200 mg twice daily, and 600 mg once daily. Using a sequential titration method, increasing from the lowest dose to the highest dose, each time after the first 4 subjects of the previous dose had completed 28 days, the results at day 28 are shown in Table 8 (PASI50 is an area and severity index of psoriasis). These PASI50 scores of 81.8% for the 600 mg once daily dose are unprecedented compared to other JAK inhibitors in development for the treatment of psoriasis. For example, 5 mg tofacitinib (also known as tasocitinib) showed a lower PASI50 score of 65.3% at week 12 (published October 7, 2010 at http: / / press.pfizer.com). The 5 mg tofacitinib dose is the dosage level approved for RA in the United States for safety reasons.

[0221] [Table 18]

[0222] Example 6. Open-label Phase II Study in Patients with Myelofibrosis The study enrolled patients aged 18 years or older with a diagnosis of primary myelofibrosis (PMF) or post-polycythemia vera MF or post-essential thrombocythemia MF (JAK2V617F positive or negative mutation status), platelet count ≥ 50 × 109 / L, hemoglobin level ≥ 8.0 g / dL (transfusion acceptable to achieve these levels), DIPSS intermediate-1 or higher, and a palpable spleen or prior splenectomy. Three different dose cohorts were evaluated: (1) 100 mg SR3 tablet twice daily; (2) 200 mg (2 × 100 mg SR3 tablets) twice daily; and (3) 600 mg (6 × 100 mg SR3 tablets) once daily. Figure 5(a)-(b) show interim results for the proportion of subjects in each dose group who achieved a ≥50% reduction in total symptom score (TSS) from the Myelofibrosis Symptom Assessment Form (MFSAF) modified v3.0 electronic diary at week 12 compared to baseline. (The MFSAF modified v3.0 includes 19 questions assessing MF-related symptoms on a scale of 0 (no symptoms) to 10 (worst symptoms imaginable).) Figure 5(a) shows the proportion (%) of patients by dose cohort (100 mg bid, 200 mg bid, and 600 mg qd) who achieved a ≥50% reduction in TSS at week 12 (patients who discontinued prior to the week 12 visit were considered non-responders). Figure 5(b) shows the percent change in TSS from baseline at week 12 by dose cohort (100 mg bid, 200 mg bid, and 600 mg qd) (only patients with baseline and week 12 data were included). Figure 6(a) shows the mean hemoglobin levels (g / dL) over time by dose cohort (100 mg bid, 200 mg bid, and 600 mg qd) (interim results for all patients). Figure 6(b) shows the mean hemoglobin levels (g / dL) over time by dose cohort (100 mg bid, 200 mg bid, and 600 mg qd) at week 48.Figure 6(c) shows the mean hemoglobin levels (g / dL) over time at week 48 as an average of the three dose cohorts, by dose cohort, compared to individuals who received placebo or ruxolitinib (ruxolitinib administered according to the Jakafi® label). The data shows an increase in hemoglobin levels at the 600 mg once daily dose. Finally, Table 9 below shows the interim blood test results (new and worsening) for each dose cohort. Table 9a shows the blood test results (new and worsening) for each dose cohort after extended exposure.

[0223] [Table 19]

[0224] [Table 20]

[0225] Example A: In vitro JAK kinase assay Compounds of formula I herein were tested for inhibitory activity of JAK targets according to the following in vitro assay described in Park et al., Analytical Biochemistry 1999, 269, 94-104. The catalytic domains of human JAK1 (aa 837-1142) and JAK2 (aa 828-1132) with N-terminal His tags were expressed using baculovirus in insect cells and purified. The catalytic activity of JAK1 and JAK2 was assayed by measuring the phosphorylation of a biotinylated peptide. The phosphorylated peptide was detected by homogeneous time-resolved fluorescence (HTRF). The IC of the compounds 50was measured for each kinase in 40 μL reactions containing enzyme, ATP, and 500 nM peptide in 50 mM Tris (pH 7.8) buffer with 100 mM NaCl, 5 mM DTT, and 0.1 mg / mL (0.01%) BSA. An IC of 1 mM 50 For the measurements, the ATP concentration in the reaction was 1 mM. The reaction was carried out at room temperature for 1 hour and then stopped with 20 μL of 45 mM EDTA, 300 nM SA-APC, 6 nM Eu-Py20 in assay buffer (Perkin Elmer, Boston, MA). Binding to europium-labeled antibody was carried out for 40 minutes and the HTRF signal was measured on a Fusion plate reader (Perkin Elmer, Boston, MA). IC of compounds of formula I and adipate at JAK1 50 had a JAK2 / JAK1 ratio >10 (measured at 1 mM ATP) and <5 nM (measured at 1 mM ATP).

[0226] Example B: Cellular Assay Cancer cell lines that are dependent on cytokines for growth and therefore on JAK / STAT signal transduction can be plated at 6000 cells per well (96-well plate format) in RPMI1640, 10% FBS, and 1 nG / mL of the appropriate cytokine. Compounds can be added to the cells in DMSO / medium (final concentration 0.2% DMSO) and incubated for 72 hours at 37° C., 5% CO2. The effect of compounds on cell viability is assessed using a CellTiter-Glo fluorescent cell viability assay (Promega) followed by TopCount (Perkin Elmer, Boston, MA) quantification. Potential off-target effects of compounds are measured in parallel using non-JAK-driven cell lines with identical assay measurements. All experiments are typically performed in duplicate.

[0227] The above cell lines can also be used to examine the effect of compounds on phosphorylation of JAK kinases or potential downstream substances such as STAT proteins, Akt, Shp2, or Erk. These experiments can be performed after overnight cytokine starvation followed by a short pre-incubation with the compounds (up to 2 hours) and cytokine stimulation for up to about 1 hour. Proteins are then extracted from the cells and analyzed by techniques well known to those skilled in the art, including Western blotting or ELISA, using antibodies capable of differentiating between phosphorylated and total proteins. These experiments can utilize normal or cancer cells to investigate the activity of compounds on tumor cell survival biology or mediators of inflammatory diseases. For example, with regard to the latter, cytokines such as IL-6, IL-12, IL-23, or IFN can be used to stimulate activation of JAKs, leading to phosphorylation of STAT proteins and potentially transcriptional profiles (assessed by array or qPCR techniques), or production and / or secretion of proteins such as IL-17. The ability of compounds to inhibit these cytokine-mediated effects can be measured using techniques common to those skilled in the art.

[0228] The compounds herein can also be tested in cell models designed to assess their potency and activity against mutant JAK, such as the JAK2V617F mutation found in myeloproliferative disorders. These experiments often utilize cytokine-dependent cells of blood lineage (e.g., BaF / 3) in which wild-type or mutant JAK kinases are ectopically expressed (James, C et al., Nature 434:1144-1148; Staerk, J et al., JBC 280:41893-41899). Evaluations include the effects of compounds on cell survival, proliferation, and phosphorylated JAK, STAT, Akt, or Erk proteins.

[0229] Certain compounds described herein can be evaluated for their activity in inhibiting T cell proliferation. Such assays can be considered as second cytokine (i.e., JAK)-driven proliferation assays and can be considered as simplified assays of immune suppression or inhibition of immune activation. Below is a brief overview of how such experiments can be performed. Peripheral blood mononuclear cells (PBMCs) can be prepared from human whole blood samples using Ficoll Hypaque separation method, and T cells (fraction 2000) can be obtained from PBMCs by washing. Freshly isolated human T cells are cultured at 2×10 in culture medium (RPMI1640 supplemented with 10% fetal bovine serum, 100 U / ml penicillin, 100 μg / ml streptomycin). 6 The cells can be maintained at a density of 1000 cells / ml for up to 2 days at 37°C. For IL-2 stimulated cell proliferation assay, T cells are first treated with phytohemagglutinin (PHA) at a final concentration of 10 μg / mL for 72 hours. After one wash with PBS, 6000 cells per well are plated in 96-well plates and treated with different concentrations of compounds in culture medium in the presence of 100 U / mL human IL-2 (ProSpec-Tany TechnoGene, Rehovot, Israel). The plates are incubated at 37°C for 72 hours and the proliferation index is evaluated using CellTiter-Glo fluorescent reagent according to the protocol suggested by the manufacturer (Promega, Madison, WI).

[0230] Example C: In vivo antitumor efficacy The compounds herein can be evaluated in human tumor xenograft models in immune-compromised mice. For example, a tumorigenic variant of the INA-6 plasmacytoma cell line can be used to subcutaneously inoculate SCID mice (Burger, R. et al., Hematol J. 2:42-53, 2001). Tumor-bearing animals can then be randomized into drug- or vehicle-treated groups, and different doses of compound can be administered by any number of conventional routes, including orally, intraperitoneally, or by continuous infusion using an implanted pump. Tumor growth is tracked over time using calipers. Additionally, tumor samples can be taken at any time after the start of treatment for the above-mentioned analysis (Example B) to evaluate the effect of the compound on JAK activity and downstream signaling pathways. In addition, the selectivity of the compound(s) can be evaluated using xenograft tumor models driven by other known kinases (e.g., Bcr-Abl), such as the K562 tumor model.

[0231] Example D: Mouse skin contact delayed-type hypersensitivity response test Compounds herein can also be tested for their efficacy (inhibiting JAK target) in T cell-driven mouse delayed type hypersensitivity test model. Mouse skin contact delayed type hypersensitivity (DTH) response is considered to be an effective model of clinical contact dermatitis and other cutaneous T-lymphocyte-mediated immune disorders, such as psoriasis (Immunol Today.1998 Jan;19(1):37-44). Mouse DTH shares several characteristics with psoriasis, including immune infiltrates, concomitant elevation of inflammatory cytokines, and keratinocyte hyperproliferation. In addition, many drugs that are useful for treating psoriasis in the clinic are also effective inhibitors of DTH response in mice (Agents Actions.1993 Jan;38(1-2):116-21).

[0232] On days 0 and 1, Balb / c mice are sensitized by topical application of the antigen 2,4,dinitro-fluorobenzene (DNFB) to their shaved abdomen. On day 5, ear thickness is measured using an engineer's micrometer. This measurement is recorded and used as a baseline. The animals are then challenged on both ears by topical application of a total of 20 μL (10 μL to the inner pinna and 10 μL to the outer pinna) of DNFB at a concentration of 0.2%. 24-72 hours after challenge, the ears are measured again. Treatment with the test compound was given throughout the sensitization and challenge phase (day -1 to day 7) or before and throughout the challenge phase (usually day 4 afternoon to day 7). Treatment with the test compound (at different concentrations) is administered either systemically or locally (topical application of treatment to the ear). The efficacy of the test compound is indicated by a reduction in ear swelling compared to the untreated condition. A compound is considered effective if it produces a reduction of 20% or more. In some experiments, mice are challenged but not sensitized (negative control).

[0233] The inhibitory effect of the test compound (inhibiting the activation of the JAK-STAT pathway) can be confirmed by immunohistochemical analysis. Activation of the JAK-STAT pathway(s) results in the formation and translocation of functional transcription factors. Furthermore, the influx of immune cells and the increased proliferation of keratinocytes should also result in unique expression profile changes in the ear, which can be investigated and quantified. Formalin-fixed and paraffin-embedded ear sections (taken after the challenge stage in the DTH model) are subjected to immunohistochemical analysis using an antibody that specifically interacts with phosphorylated STAT3 (clone 58E12, Cell Signaling Technologies). Mice ears are treated with the test compound, vehicle, or dexamethasone (a clinically effective treatment for psoriasis) or no treatment at all in the DTH model for comparison. The test compound and dexamethasone can generate similar transcriptional changes, both qualitatively and quantitatively, and both the test compound and dexamethasone can reduce the number of infiltrating cells. Both systemic and local administration of test compounds can produce inhibitory effects, ie, reduction in the number of infiltrating cells and inhibition of transcriptional changes.

[0234] Example E: Anti-inflammatory activity in vivo The compounds of the present invention can be evaluated in rodent or non-rodent models designed to reproduce single or multiple inflammatory responses.For example, rodent models of arthritis can be used to evaluate the therapeutic potential of compounds administered prophylactically or therapeutically.These models include, but are not limited to, mouse or rat collagen-induced arthritis, rat adjuvant-induced arthritis, and collagen antibody-induced arthritis.Autoimmune diseases, including, but not limited to, multiple sclerosis, type I diabetes, uveitis retinalis, thyroiditis, myasthenia gravis, immunoglobulin nephropathy, myocarditis, airway sensitization (asthma), lupus, or colitis, can also be used to evaluate the therapeutic potential of the compounds of the present invention. These models are well established in the research community and familiar to those skilled in the art (Current Protocols in Immunology, Vol 3., Coligan, JE et al., Wiley Press.; Methods in Molecular Biology: Vol. 225, Inflammation Protocols., Winyard, PG and Willoughby, DA, Humana Press, 2003.).

[0235] Example F: Animal Models for Treatment of Dry Eye, Uveitis, and Conjunctivitis Agents may be evaluated in one or more preclinical models of dry eye known to those skilled in the art, including, but not limited to, the rabbit concanavalin A (ConA) lacrimal gland model, the scopolamine mouse model (subcutaneous or transdermal), the botulinum mouse lacrimal gland model, or any of the many spontaneous rodent autoimmune models resulting in ocular gland dysfunction (e.g., NOD-SCID, MRL / lpr, or NZB / NZW) (Barabino et al., Experimental Eye Research 2004, 79, 613-621 and Schrader et al., Developmental Ophthalmology, Karger 2008, 41, 298-312, each of which is incorporated herein by reference in its entirety). Evaluations in these models may include histopathology of the ocular glands and eyes (such as the cornea) and, optionally, the classic Schirmer test or a modified version thereof (Barabino et al.) to measure tear production. Activity can be assessed by dosing via multiple routes of administration (eg, systemic or local), which may begin before or after measurable disease is present.

[0236] Agents may be evaluated in one or more preclinical models of uveitis known to those skilled in the art. These include, but are not limited to, experimental autoimmune uveitis (EAU) and endotoxin-induced uveitis (EIU) models. EAU experiments may be performed in rabbits, rats, or mice and may involve passive or active immunization. For example, any of a number of retinal antigens may be used to sensitize animals to the relevant immunogen, and the animals may then be ocularly challenged with the same antigen. The EIU model is more acute and involves local or systemic administration of a sublethal dose of lipopolysaccharide. Evaluations for both the EIU and EAU models may include fundus examination, histopathology, among others. These models have been reviewed by Smith et al. (Immunology and Cell Biology 1998,76,497-512, which is incorporated herein by reference in its entirety). Activity is assessed by dosing via multiple routes of administration (e.g., systemic or local), which may begin before or after the presence of measurable disease. Some of the models listed above may also develop scleritis / episcleritis, choroiditis, cyclitis, or iritis, making them useful in investigating the potential activity of compounds for the therapeutic treatment of these diseases.

[0237] Agents may be evaluated in one or more preclinical models of conjunctivitis known to those skilled in the art. These include, but are not limited to, rodent models utilizing guinea pigs, rats, or mice. Guinea pig models include models utilizing active or passive immunization and / or immune challenge protocols with antigens such as ovalbumin or ragweed (reviewed in Groneberg, DA et al., Allergy 2003, 58, 1101-1113, incorporated herein by reference in its entirety). Rat and mouse models are similar in general design to models in guinea pigs (also reviewed by Groneberg). Activity may be evaluated by dosing via multiple routes of administration (e.g., systemic or topical), which may begin before or after measurable disease is present. Endpoints in such studies may include, for example, histological, immunological, biochemical, or molecular analysis of ocular tissues such as the conjunctiva.

[0238] Example G: In vivo protection of bone Compounds may be evaluated in various preclinical models of osteopenia, osteoporosis, or bone resorption that are well known to those skilled in the art. For example, ovariectomized rodents may be used to evaluate the ability of compounds to affect the signs and markers of bone remodeling and / or bone density (WSS Jee and W. Yao, J Musculoskel.Nueron.Interact., 2001,1(3),193-207, which are incorporated herein by reference in their entirety). Alternatively, bone density and bone structure may be evaluated in control or compound-treated rodents in models in which osteopenia is induced by treatment (e.g., glucocorticoids) (Yao et al., Arthritis and Rheumatism, 2008,58(6),3485-3497; and supra, supra, 58(11),1674-1686, both of which are incorporated herein by reference in their entirety). In addition, the effect of compounds on bone resorption and bone density can be evaluated in rodent models of arthritis as described above (Example E). The endpoints for all of these models can vary but often include histological and radiological evaluations, as well as immunohistology and appropriate biochemical markers of bone remodeling. The present invention includes the following aspects. [1] A method for treating an autoimmune disease, cancer, a myeloproliferative disease, an inflammatory disease, a bone resorption disease, or organ transplant rejection in a patient in need thereof, comprising administering to the patient a compound comprising the steps of: (a) administering to the patient a compound having the formula (I) or (II) a medicament for treating an autoimmune disease, a cancer, a myeloproliferative disease, an inflammatory disease, a bone resorption disease, or an organ transplant rejection in a patient in need thereof, the compound comprising the steps of administering to the patient a compound having the formula (I) or a medicament for treating an autoimmune disease, a cancer, a myeloproliferative disease, an inflammatory disease, a bone resorption disease, or an organ transplant rejection in a patient in need thereof, the compound comprising the compound having the formula (I) or (II) ... organ transplant, the compound having the formula (I) or (II) a orally administering to the patient a once daily dose of about 400 mg to about 600 mg at 200 mg / kg, wherein the dose comprises one or more sustained release dosage forms each comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof. [2] The method of [1], wherein the method comprises administering to the patient the one or more sustained release dosage forms as a once-daily dosage of about 600 mg, on a free base basis, of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutical acceptable salt thereof. [3] The method of [1], wherein the one or more sustained release dosage forms are six dosage forms of about 100 mg on a free base basis of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutical acceptable salt thereof. [4] The method of [1], wherein the one or more sustained release dosage forms are three dosage forms of about 200 mg on a free base basis of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutical acceptable salt thereof. [5] The method of [1], wherein the one or more sustained release dosage forms are two dosage forms of about 300 mg on a free base basis of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutical acceptable salt thereof. [6] The method of [1], wherein the one or more sustained release dosage forms are one dosage form of about 600 mg of free base of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutical acceptable salt thereof. [7] The method according to any one of [1] to [6], wherein the autoimmune disease is a skin disorder, multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, type I diabetes, lupus, inflammatory bowel disease, Crohn's disease, myasthenia gravis, immunoglobulin nephropathy, myocarditis, autoimmune thyroid disease, atopic dermatitis, psoriasis, skin sensitization, skin irritation, skin rash, contact dermatitis or allergic contact sensitization. [8] The method according to any one of [1] to [6], wherein the autoimmune disease is rheumatoid arthritis. [9] The method according to [8], wherein the patient's ACR70 score is greater than about 40%.

[10] The method according to [8], wherein the patient's ACR70 score is greater than about 50%.

[11] The method according to any one of [1] to [6], wherein the autoimmune disease is psoriasis.

[12] The method described in

[11] requires a PASI50 score of more than approximately 70%.

[13] The method according to any one of [1] to [6], wherein the cancer is prostate cancer, renal cancer, liver cancer, breast cancer, lung cancer, thyroid cancer, Kaposi's sarcoma, Castleman's disease, pancreatic cancer, lymphoma, leukemia, multiple myeloma, polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis with myeloid metaplasia (MMM), primary myelofibrosis (PMF), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), hypereosinophilic syndrome (HES), idiopathic myelofibrosis (IMF), or systemic mastocytosis (SMCD).

[14] The method according to any one of [1] to [6], wherein the myeloproliferative disease is primary myelofibrosis (PMF).

[15] The method described in

[14] , wherein the method results in a decrease in the patient's total symptom score (TSS) compared to baseline.

[16] The method according to

[14] , wherein the method results in a reduction in anemia.

[17] The method according to any one of [1] to [6], wherein the bone resorption disease is osteoporosis, osteoarthritis, bone resorption associated with hormonal imbalance, bone resorption associated with hormone therapy, bone resorption associated with an autoimmune disease, or bone resorption associated with cancer.

[18] The mean time to maximum plasma concentration (T) of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile provided by oral administration of one or more sustained-release dosage forms to fasting individuals. max The method according to any one of [1] to

[17] , wherein the reaction time is from about 0.5 hours to about 3 hours.

[19] The mean time to maximum plasma concentration (T) of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile provided by oral administration of one or more sustained-release dosage forms to fasting individuals. max ) is at least 0.5 hours.

[20] Oral administration of one or more sustained-release dosage forms to fasting individuals provided mean peak plasma concentrations (C max ) mean 12-hour plasma concentration (C 12h The method according to any one of [1] to

[19] , wherein the ratio of the α-amino acid to the α-amino acid is about 5 to about 50.

[21] Oral administration of one or more sustained-release dosage forms to fasting individuals provided mean peak plasma concentrations (C max ) mean 12-hour plasma concentration (C 12h The method according to any one of [1] to

[19] , wherein the ratio of the α-amino acid to the β-amino acid is from about 9 to about 40.

[22] Oral administration of one or more sustained-release dosage forms to fasting individuals provided mean peak plasma concentrations (C max ) mean 12-hour plasma concentration (C 12h The method according to any one of [1] to

[19] , wherein the ratio of the α-amino acid to the β-amino acid is about 15 to about 30.

[23] The mean half-life (t 1 / 2 The method according to any one of [1] to

[22] , wherein the time required for the reaction is from about 1 hour to about 20 hours.

[24] Oral administration of one or more sustained-release dosage forms to individuals after a high-fat meal provides the mean time to maximum plasma concentration (T max The method according to any one of [1] to

[22] , wherein the time required for the incubation is about 1 hour to about 9 hours.

[25] Oral administration of one or more sustained-release dosage forms to individuals after a high-fat meal provides the mean time to maximum plasma concentration (T max 22. The method according to any one of claims 1 to 22, wherein the time required for the incubation is at least 1.5 hours.

[26] Oral administration of one or more sustained-release dosage forms to individuals after a high-fat meal provided mean peak plasma concentrations (C max ) mean 12-hour plasma concentration (C 12h The method according to any one of [1] to

[25] , wherein the ratio of the amount of the ion exchange polymer to the amount of the ion exchange polymer is from about 10 to about 70.

[27] Oral administration of one or more sustained-release dosage forms to individuals after a high-fat meal provided mean peak plasma concentrations (C max ) mean 12-hour plasma concentration (C 12h The method according to any one of [1] to

[25] , wherein the ratio of the amount of the cation to the amount of the cation is about 15 to about 50.

[28] Oral administration of one or more sustained-release dosage forms to individuals after a high-fat meal provided mean peak plasma concentrations (C max ) mean 12-hour plasma concentration (C 12h The method according to any one of [1] to

[25] , wherein the ratio of the α-amino acid to the β-amino acid is about 25 to about 45.

[29] The mean half-life (t 1 / 2 The method according to any one of [1] to

[28] , wherein the time required for the incubation is about 1 hour to about 7 hours.

[30] The mean half-life (t 1 / 2 The method according to any one of [1] to

[28] , wherein the time required for the incubation is about 2 hours to about 5 hours.

[31] The method of any one of [1] to

[30] , wherein the one or more sustained release dosage forms are each a tablet.

[32] The method of any one of [1] to

[31] , wherein the one or more sustained release dosage forms are prepared by a process comprising wet granulation.

[33] The method of any one of [1] to

[32] , wherein the one or more sustained release dosage forms each contain one or more hypromelloses.

[34] The method of any one of [1] to

[32] , wherein the one or more sustained release dosage forms each contain one or more excipients independently selected from hypromellose and microcrystalline cellulose.

[35] The method of any one of [1] to

[34] , wherein the one or more sustained release dosage forms each comprise one or more excipients independently selected from hypromellose, microcrystalline cellulose, magnesium stearate, lactose, and lactose monohydrate.

[36] The method of any one of [1] to

[32] , wherein the one or more sustained release dosage forms each comprise a first hypromellose characterized by having an apparent viscosity of about 80 cP to about 120 cP at a 2% concentration in water and a second hypromellose characterized by having an apparent viscosity of about 3000 cP to about 5600 cP at a 2% concentration in water.

[37] The method of any one of [1] to

[32] , wherein the one or more sustained release dosage forms each contain from about 10% by weight to about 15% by weight of one or more hypromelloses.

[38] The method of any one of [1] to

[32] and

[37] , wherein the one or more sustained release dosage forms each contain about 16% to about 22% by weight of microcrystalline cellulose.

[39] The method of any one of [1] to

[32] and

[37] to

[38] , wherein the one or more sustained release dosage forms each contain about 45% to about 55% by weight of lactose monohydrate.

[40] The method of any one of [1] to

[17] and

[37] to

[39] , wherein the one or more sustained release dosage forms each contain from about 0.3% to about 0.7% by weight of magnesium stearate.

[41] The method according to any one of [1] to

[40] , wherein the salt is {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile adipate.

[42] One or more sustained release dosage forms, which together provide a patient with a once-daily oral dosage of about 600 mg, on a free base basis, of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof.

[43] A dosage comprising one or more sustained release dosage forms, the dosage providing a patient with a once-daily oral dosage of about 600 mg, based on the free base, of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutical acceptable salt thereof.

[44] One or more sustained release dosage forms each comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof, wherein the one or more sustained release dosage forms together provide a patient with a once-daily oral dosage of about 400 mg to about 600 mg of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof.

[45] A dosage comprising one or more sustained release dosage forms each comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof, wherein the dosage provides a patient with a once-daily oral dosage of about 400 mg to about 600 mg of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof, on a free base basis.

Claims

1. 1. A method for treating an autoimmune disease, cancer, a myeloproliferative disease, an inflammatory disease, a bone resorption disease, or organ transplant rejection in a patient in need thereof, comprising administering to a patient a compound comprising the steps of: orally administering to said patient a once daily dose of about 400 mg to about 600 mg at 200 mg / kg, said dose comprising one or more sustained release dosage forms each comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof.

2. 2. The method of claim 1, wherein said method comprises administering to said patient one or more sustained release dosage forms as a once-daily dosage of about 600 mg, on a free base basis, of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutical acceptable salt thereof.

3. 2. The method of claim 1, wherein the one or more sustained release dosage forms are six dosage forms of about 100 mg on a free base basis of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof.

4. 2. The method of claim 1, wherein the one or more sustained release dosage forms are three dosage forms of about 200 mg on a free base basis of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof.

5. 2. The method of claim 1, wherein the one or more sustained release dosage forms are two dosage forms of about 300 mg on a free base basis of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof.

6. 2. The method of claim 1, wherein the one or more sustained release dosage forms is one dosage form of about 600 mg on a free base basis of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof.

7. 7. The method of any one of claims 1 to 6, wherein the autoimmune disease is a skin disorder, multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, type I diabetes, lupus, inflammatory bowel disease, Crohn's disease, myasthenia gravis, immunoglobulin nephropathy, myocarditis, autoimmune thyroid disease, atopic dermatitis, psoriasis, skin sensitization, skin irritation, skin rash, contact dermatitis or allergic contact sensitization.

8. The method of any one of claims 1 to 6, wherein the autoimmune disease is rheumatoid arthritis.

9. 9. The method of claim 8, wherein the patient has an ACR70 score of greater than about 40%.

10. 9. The method of claim 8, wherein the patient has an ACR70 score of greater than about 50%.

11. 7. The method of any one of claims 1 to 6, wherein the autoimmune disease is psoriasis.

12. 12. The method of claim 11, wherein the PASI50 score is greater than about 70%.

13. 7. The method of any one of claims 1 to 6, wherein the cancer is prostate cancer, renal cancer, liver cancer, breast cancer, lung cancer, thyroid cancer, Kaposi's sarcoma, Castleman's disease, pancreatic cancer, lymphoma, leukemia, multiple myeloma, polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis with myeloid metaplasia (MMM), primary myelofibrosis (PMF), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), hypereosinophilic syndrome (HES), idiopathic myelofibrosis (IMF), or systemic mastocytosis (SMCD).

14. 7. The method of any one of claims 1 to 6, wherein the myeloproliferative disorder is primary myelofibrosis (PMF).

15. 15. The method of claim 14, wherein the method results in a decrease in the patient's Total Symptom Score (TSS) compared to baseline.

16. 15. The method of claim 14, wherein the method results in a reduction in anemia.

17. 7. The method according to any one of claims 1 to 6, wherein the bone resorption disease is osteoporosis, osteoarthritis, bone resorption associated with hormonal imbalance, bone resorption associated with hormone therapy, bone resorption associated with an autoimmune disease, or bone resorption associated with cancer.

18. Oral administration of one or more sustained release dosage forms to a fasting individual provides mean time to maximum plasma concentration (T max18. The method of claim 1, wherein the reaction time is from about 0.5 hours to about 3 hours.

19. Oral administration of one or more sustained release dosage forms to a fasting individual provides mean time to maximum plasma concentration (T max 18. The method of claim 1, wherein the reaction time is at least 0.5 hours.

20. Oral administration of one or more sustained release dosage forms to a fasting individual provides mean peak plasma concentrations (C max ) mean 12-hour plasma concentration (C 12h 20. The method of claim 1, wherein the ratio of (i) to (ii) is from about 5 to about 50.

21. Oral administration of one or more sustained release dosage forms to a fasting individual provides mean peak plasma concentrations (C max ) mean 12-hour plasma concentration (C 12h 20. The method of claim 1, wherein the ratio of (i) to (ii) is from about 9 to about 40.

22. Oral administration of one or more sustained release dosage forms to a fasting individual provides mean peak plasma concentrations (C max ) mean 12-hour plasma concentration (C 12h 20. The method of claim 1, wherein the ratio of (a) to (b) is from about 15 to about 30.

23. Oral administration of one or more sustained release dosage forms to a fasted individual provides a mean half-life (t 1/2 23. The method of claim 1, wherein the reaction time is from about 1 hour to about 20 hours.

24. Oral administration of one or more sustained release dosage forms to an individual after a high-fat meal provides mean time to maximum plasma concentration (T max 23. The method of claim 1, wherein the reaction time is from about 1 hour to about 9 hours.

25. Oral administration of one or more sustained release dosage forms to an individual after a high-fat meal provides mean time to maximum plasma concentration (T max 23. The method of claim 1, wherein the time period during which the reaction is continued for 1.5 hours is at least 1.5 hours.

26. Oral administration of one or more sustained release dosage forms to an individual after a high-fat meal provides mean maximum plasma concentrations (C max ) mean 12-hour plasma concentration (C 12h 26. The method of claim 1, wherein the ratio of (i) to (ii) is from about 10 to about 70.

27. Oral administration of one or more sustained release dosage forms to an individual after a high-fat meal provides mean maximum plasma concentrations (C max ) mean 12-hour plasma concentration (C 12h 26. The method of claim 1 , wherein the ratio of (a) to (b) is from about 15 to about 50.

28. Oral administration of one or more sustained release dosage forms to an individual after a high-fat meal provides mean maximum plasma concentrations (C max ) mean 12-hour plasma concentration (C 12h 26. The method of claim 1, wherein the ratio of (a) to (b) is from about 25 to about 45.

29. Oral administration of one or more sustained release dosage forms to an individual after a high-fat meal provides the mean half-life (t 1/229. The method of any one of claims 1 to 28, wherein the reaction time is from about 1 hour to about 7 hours.

30. Oral administration of one or more sustained release dosage forms to an individual after a high-fat meal provides the mean half-life (t 1/2 29. The method of any one of claims 1 to 28, wherein the reaction time is from about 2 hours to about 5 hours.

31. 31. The method of any one of claims 1 to 30, wherein the one or more sustained release dosage forms are each a tablet.

32. 32. The method of any one of claims 1 to 31, wherein the one or more sustained release dosage forms are prepared by a process comprising wet granulation.

33. 33. The method of any one of claims 1 to 32, wherein the one or more sustained release dosage forms each comprise one or more hypromelloses.

34. 33. The method of any one of claims 1 to 32, wherein the one or more sustained release dosage forms each comprise one or more excipients independently selected from hypromellose and microcrystalline cellulose.

35. 35. The method of any one of claims 1 to 34, wherein the one or more sustained release dosage forms each comprise one or more excipients independently selected from hypromellose, microcrystalline cellulose, magnesium stearate, lactose, and lactose monohydrate.

36. 33. The method of any one of claims 1 to 32, wherein the one or more sustained release dosage forms each comprise a first hypromellose characterized by having an apparent viscosity of about 80 cP to about 120 cP at a 2% concentration in water and a second hypromellose characterized by having an apparent viscosity of about 3000 cP to about 5600 cP at a 2% concentration in water.

37. 33. The method of any one of claims 1 to 32, wherein the one or more sustained release dosage forms each comprise from about 10% to about 15% by weight of the one or more hypromelloses.

38. 38. The method of any one of claims 1 to 32 and 37, wherein the one or more sustained release dosage forms each comprise about 16% to about 22% by weight of microcrystalline cellulose.

39. 39. The method of any one of claims 1 to 32 and 37 to 38, wherein the one or more sustained release dosage forms each contain about 45% to about 55% by weight of lactose monohydrate.

40. 40. The method of any one of claims 1-17 and 37-39, wherein the one or more sustained release dosage forms each comprise from about 0.3% to about 0.7% by weight of magnesium stearate.

41. 41. The method of any one of claims 1 to 40, wherein the salt is {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile adipate.

42. One or more sustained release dosage forms, which together provide a patient with a once-daily oral dosage of about 600 mg, on a free base basis, of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof.

43. 1. A dosage comprising one or more sustained release dosage forms, the dosage providing a patient with a once daily oral dosage of about 600 mg, based on the free base, of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutical acceptable salt thereof.

44. 1. One or more sustained release dosage forms each comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof, wherein said one or more sustained release dosage forms together provide a patient with a once daily oral dosage of from about 400 mg to about 600 mg, on a free base basis, of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof.

45. 1. A dose comprising one or more sustained release dosage forms each comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof, wherein said dose provides a patient with a once daily oral dosage of about 400 mg to about 600 mg, on a free base basis, of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharma- ceutically acceptable salt thereof.